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Abstract 
  Understanding how an epigenetic regulator such as ATP-dependent chromatin-
remodeling complexes modulate processes such as development and/or immune 
response is essential for our comprehension of cell biology. Deletion of the ATP-
dependent chromatin remodeling factor INO80 is known to be embryonically lethal, 
however, the mechanism is not known. To identify roles for INO80 in mouse early 
development we generated Ino80 KO mice. Ino80 KO ESCs (Embryonic stem cells) 
were viable when maintained at ground state pluripotency but fail to differentiate in vitro 
and in vivo. Gene expression analysis of Ino80 KO early embryos by in situ 
hybridization showed elevated Bmp4 expression and reduced expression of DVE (distal 
visceral endoderm) markers Cer1, Hex, and Lefty1. BMP4 is a known negative regulator 
of DVE differentiation in the early embryo. Molecular studies in Ino80 KO ESCs 
demonstrated that INO80 is bound to the Bmp4 promoter, and regulates its chromatin 
structure, to suppress the positive regulator SP1 from stimulating its transcription. 
These results, suggest that INO80 directly regulates the chromatin structure of 
the Bmp4 promoter with consequences to mouse embryo development. These results 
are significant because they demonstrate a specific role of INO80 in establishing P-D 
embryonic axis.  
 NURF (Nucleosome   remodeling factor) is another ATP-dependent chromatin 
remodeling complex that is overexpressed in many cancer types including breast 
cancer. To demonstrate the roles of NURF in breast cancer biology, we knocked-down 
the NURF essential subunit BPTF (bromodomain PHD finger transcription factor) in  
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mouse breast cancer cell lines. Transplantation of these cell lines into immune-
competent mice revealed that BPTF KD enhances NK cell antitumor activity. BPTF KD 
enhanced NK-92 cytotoxic activity toward BPTF KD cells by NKp30 activation in vitro. 
NK-92 activity is reduced by the addition of heparin to the culture medium, further 
indicating the involvement of NKp30 (in human) and NCR1 (in mice) in killing of tumor 
cells. We found that BPTF controls the abundance of NKp30/NCR1 ligands (heparin 
sulfate proteoglycans (HSPGs) by regulation of heparanase expression 
(endoglycosidase that degrades HSPGs). In addition, BPTF depletion in established 
mouse breast tumors enhanced anti-tumor immunity, without affecting NK or T cell 
cytotoxic activity, providing a novel immunotherapy target. 
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PART I. Role of the Nucleosome Remodeling Factor INO80 in Development 
Chapter 1. Background and Literature Review 
 
1.1 DNA Packaging into Chromatin  
 The eukaryotic genetic information is stored in two meters of linear DNA. In order 
for this long DNA to fit into a 10 µm nucleus it has to be packaged into chromatin, which 
consists of DNA wrapped around histone proteins. Histone proteins are highly 
conserved proteins, and they are the main components of chromatin structure. The 
basic unit of chromatin structure is the nucleosome, which is composed of 145-147 bp 
DNA wrapped around an octamer of histones, which itself consists of two copies of the 
canonical histones H2A, H2B, H3, and H4. The nucleosome structure is stabilized by 
the interaction between negatively charged DNA and positively charged histones. It is 
also stabilized by the protein-protein interactions inside the histone octamer (Davey et 
al., 2002 and Rohs et al., 2009). Nearby nucleosomes are connected by linker DNA (10-
90 bp) and linker histones (H1 and H5) to form a chromatin fiber. Interactions between 
these fibers through inter and intra-nucleosomal interactions give rise to the highly 
compacted chromatin that we see in the chromosomes (Tremethick et al., 2007). 
 Depending on the degree of chromatin condensation, chromatin can be divided 
into euchromatin and heterochromatin (Trojer and Reinberg, 2007). Euchromatin is less 
condensed chromatin and enriched with genes. Heterochromatin is highly condensed 
and can be further divided into constitutive and facultative heterochromatin 
  
  
    
  
 
4 
 
 (Margueron et al. 2005). Constitutive heterochromatin is repetitive DNA sequences that 
are clustered at telomeres, centromeres and peri-centromeric regions of the 
chromosomes. Facultative heterochromatin is enriched with genes that are expressed 
at a specific developmental stage or in response to specific stimuli. Consequently, 
regions of facultative heterochromatin are different among different cell types. These 
different chromatin domains are separated from each other by insulator elements 
(Trojer and Reinberg, 2007). Chromatin in its high order structure is inaccessible to DBP 
(DNA binding proteins), which are involved in nuclear processes such as transcription, 
DNA replication, and DNA damage response. Therefore, cells have evolved 
mechanisms to modulate the chromatin from inaccessible to accessible conformation, 
which includes histone modifications, DNA methylation, incorporation of histone 
variants, ATP-dependent chromatin remodeling, and long non-coding RNA mediated 
modulation (C. David and Thomas, 2016). 
 
1.2 Mechanisms of Chromatin Structure Modulation 
1.2.1 Histone Modifications 
 Histones are chemically modified at the post-translation level mostly at their N-
terminal and to a lesser extent at core residues or C-termini. The N-termini of histones 
is about 19-40 amino acids enriched in basic residues mainly lysine (K) and arginine (R) 
that are extended out from the nucleosome in the form of histone tails. The interaction 
between these tails in neighboring nucleosomes, or within the same nucleosome, help 
to modulate chromatin structure. Post-translation modification (PTM) of histones could  
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be in the form of methylation, acetylation, phosphorylation or ubiquitination. The 
presence of these modifications serve as a platform for the recruitment of chromatin 
modulators or transcription factors (Andrew and Tony, 2011). 
 Methylation occurs mostly on lysine and to a lesser extent on arginine. 
Methylation can be mono-, di-, or tri- and the methylated residue can be on K4 or K36, 
which are associated with active chromatin, or on K9/K27, which are associated with 
repressed chromatin. Genome-wide analysis showed that H3K4me3 is localized at 
active TSS (transcription start sites) considering them as mark of active promoters 
(Sims et al., 2005). H3K4me1 is co-localized at enhancers with p300 histone acetyl 
transferase. The presence of active methylation marks serves to recruit chromatin 
remodeling complexes, such as NURF or the CHD1 (chromo-domain helicase DNA 
binding1), to promoter regions to facilitate gene expression (Wysocka et al., 2006). The 
H3K36me3 mark is enriched at exons than introns, suggesting a possible role in 
alternative splicing or the transcript elongation (Barski et al., 2007, Spies et al., 2009 
and Kolasinska et al., 2009).  
Acetylation mainly occurs on lysine residues and many studies showed that H4 
and H3 acetylation is a mark of open and accessible chromatin domains. Shogren- 
Knaak et al., showed that acetylation on H4K16 interferes with chromatin compaction 
(Shorgen-Knaak, et al., 2006). In addition, acetylation neutralizes the positively charged 
lysine residues on histone tails and weaken their interaction with negatively charged 
DNA, which facilitate chromatin accessibility (Luger et al., 1997). Cells with highly 
dynamic chromatin, like ESCs, have enrichment of H4K16ac at TSS of transcriptionally 
active genes (Taylor et al., 2013). 
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Phosphorylation of histones can occur on serine, threonine and tyrosine 
residues, and this modification plays a role in many processes such as chromatin 
compaction, DNA repair, and transcription. The most conserved form of histone 
phosphorylation in eukaryotes is H3 phosphorylation. Four residues are phosphorylated 
on the H3 N-termini, which are T3, S10, T11, and S28. However, the most documented 
mark is H3S10ph (histone 3 phosphorylation at serine 10). H3S10ph is associated with 
chromatin condensation during mitosis (Wei et al., 1999). In addition, the linker histone 
H1 is phosphorylated in a cell cycle-dependent manner especially during mitosis. H1 
phosphorylation by the CDC2 kinase mediates its binding to HP1 to maintain more 
stabilize compacted chromatin structure while its phosphorylation by CDK2 disrupt this 
interaction and destabilize chromatin to promote cell progression (Hale et al., 2006). 
Moreover, the phosphorylation of H3S28 is involved in transcription regulation of EGF 
(epidermal growth factor)-responsive genes such as c-fos (Lau et al., 2011). In 
response to DNA damage, the histone variant H2AX is phosphorylated by the ATM 
kinase and it is commonly referred to as γH2AX. The phosphorylation of H2AX spreads 
around the DNA damage site to recruit repair proteins such as MDC1 (Stucki et al., 
2005)  
  Ubiquitination occurs in the form of mono-ubiquitination on lysine residues. The 
most ubiquitinated histones in the nucleus are H2A and H2B. H2Aub is associated with 
repressed chromatin since H2Aub ligase is found in repression complexes such as 
PRC1 (polycomb repressive complex) (Ogawa et al., 2002). Another study showed that 
H2Aub prevents the recruitment of the histone chaperon FACT (facilitate chromatin 
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transcription) to RNAP II binding sites to facilitate transcription elongation (Zhou et al., 
2008). In addition, the activity of H2A deubiquitinase (2A-DUB) in activating gene 
expression provides another supporting evidence for H2Aub associated repression 
(Zhu et al., 2007). However, H2Bub is mostly associated with gene activation. ChIP-chip 
experiments showed enrichment of H2Bub at actively transcribed genes (Minsky et al., 
2008). ChIP-chip is chromatin immunoprecipitation (ChIP) followed by DNA microarray 
(chip) to identify the interactions between DNA and proteins in a genome wide scale 
(Aparicio et al., 2004). H2Bub is also involved in transcription elongation where they are 
required for maintaining the chromatin integrity during elongation by RNA Pol II (Xiao et 
al., 2005). 
1.2.2 Incorporation of Histone Variants 
 Histone variants are different from canonical histones mainly at the C-termini by 
length or amino acid composition (Ausió et al., 2002). The replacement of canonical 
histones with histone variants alter the nucleosome structure and consequently its 
function. For example, the replacement of H2A with its variants which includes H2AZ, 
H2AX, H2ABBD (H2A-bar-body-deficient) and macro H2A alters cellular functions in 
diverse cellular pathways. H2AZ (Htz1 is the yeast homolog) is the most studied H2A 
variant, and it is encoded by an essential gene since its disruption in mice resulted in 
early embryonic lethality (Faast et al., 2001). H2AZ is required to maintain 
heterochromatin domains through preventing the spread of HP1 to active regions in the 
genome (Rangasamy et al., 2004). H2AZ incorporation modulates chromatin structure 
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to facilitate active transcription and as such, its incorporation prevents chromatin 
condensation (Park et al., 2004). 
1.2.3 DNA Methylation  
 DNA modification by methylation is the major form of epigenetic regulation in 
which the cytosines is covalently linked to a methyl group at the primary sequence CpG 
dinucleotide. DNA methylation patterns are tissue- and cell type-specific through 
methylation of CpG at specific sites (Razin et al., 1980). DNA methylating enzymes 
Dnmt3a and Dnmt3b are involved in the de novo establishment of methylation during 
development while the Dnmt1 is required to maintain this pattern upon cell division. 
DNA methylation pattern affect the chromatin structure since hypomethylated DNA is 
associated with active chromatin while hypermethylated DNA is associated with 
repressed chromatin (Razin et al., 1977). DNA methylation silences gene expression by 
impeding the binding of positive transcription factors or the recruitment of MBPs 
(methylated DNA binding proteins), which in turn recruit a repressive complexes that 
silences gene expression. For example, the chromatin remodeling complex NURD 
(Nucleosome remodeling and histone deacetylase) contain MBD2 (Methyl binding 
domain 2) that binds methylated DNA, and this interaction stabilizes MBD2 binding and 
represses gene expression (Zhang et al., 1990). Chromatin modification drives specific 
DNA methylation, and there is a growing evidence for the interaction between histone-
modifying enzymes, such as HDAC1 (Histone deacetylase 1) and HDAC2 (Histone 
deacetylase 2), and the DNA methylating enzymes Dnmt1, Dnmt3a (Fuks et al., 2000). 
For example, transcription factors induce specific genes acetylation by recruitment of 
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HATs (Histone acetyl transferases) and RNA Pol II, and this is followed by DNA 
demethylation (D'Alessio et al., 2007). 
1.2.4 ATP-Dependent Chromatin Remodeling Complexes 
 The major regulators of chromatin structure are complexes that utilize ATP 
hydrolysis as an energy source to disrupt histone-DNA interaction, and they are known 
as ATP-dependent chromatin remodeling complexes. These complexes are involved in 
every aspect of genome metabolism such as transcription, DNA replication, gene 
expression, and DNA damage and repair responses. These complexes belong to the 
Snf2 (sucrose non-fermenting 2) family of ATP-dependent helicases, which is further 
divided into four subfamilies based on the sequence homology of the ATPase domain 
and additional domains within the ATPase subunit, which include SWI/SNF (Switching 
defective 2/sucrose non-fermenting 2) ISWI (Imitation switch); CHD (Chromodomain, 
helicase and DNA-binding) and INO80 (Inositol-requiring 80). All subfamilies share the 
highly conserved ATPase domain, including an ATP binding domain for enzymatic 
activity adjacent to a helicase domain, which is required for the remodeling function 
(Bartholomew et al., 2014). The remodeling activity could result in the sliding of a 
nucleosome, nucleosome eviction, nucleosome assembly, nucleosome spacing or 
exchanging histone variants as showed in Figure 1.1. Sliding can expose or mask 
transcription factor binding sites in DNA. Ejecting a nucleosome is required during 
nuclear processes such DNA replication, and the DNA damage response.  Exchange of 
histone variants occurs when modulating the nucleosome structure, such as the 
deposition of γH2AX variant of H2A during a DNA damage response (Becker et al., 
2013).  
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Figure 1.1: The Effect of ATP-Dependent Nucleosome Remodeling. 
A) Remodeling can result in change of position or composition of nucleosomes. 
B) ATP-dependent remodeler can cooperate with histone chaperones to assemble nucleosomes. 
C) ATP-dependent remodeler can arrange the distances between nucleosomes during nucleosome     
spacing. (Becker et al., 2013). 
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1.3 Chromatin Remodeling and Development 
 ATP-dependent chromatin remodeling complexes are crucial for chromatin 
dynamic structure (assembly & disassembly) and regulation. Now, it is conceivable that 
these complexes have evolved as an adaptation to the major changes in chromatin 
regulation. During their evolution, they have expanded their gene families and utilized 
different combinatorial assemblies to form several hundred complexes with diverse 
biological functions beyond transcription in a different context (Wu et al., 2009).  
1.3.1The SWI/SNF or BAF Complexes  
  BAF complexes change their subunit composition during ESCs differentiation 
from pluripotent to multipotent progenitor cell to a unipotent committed cell. The ATPase 
subunit of BAF complexes is encoded by two genes, Brm and Brg1 (Brahma-related 
gene 1), and each complex contains only one of them. BAF complexes with different 
ATPase subunit exhibit diverse roles in different cell types (Lessard et al., 2007). In 
mammals, mRNA of oocytes is degraded after fertilization and zygote genes must be 
activated to initiate cell division. Brg1 is crucial for zygotic gene activation and, maternal 
KO of Brg1 results in four-cell stage embryo that cannot undergo cleavage division 
(Scott et al., 2006). Brg1 null embryos die before implantation stage where Brg1 is 
required for ICM (inner cellular mass) and trophoblast cell survival through regulation of 
self-renewal and pluripotency genes (Scott et al., 2000). However, Brm null embryos 
develop normally with increased body weight that could be a result of high proliferation 
rates. Brm null MEFs fail to arrest the cell cycle in response to cell confluency or DNA 
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damage, suggesting that Brm is involved in the regulation of cell growth (Reyes et al., 
1998). 
1.3.2 ISWI Complexes 
 The core ATPase of ISWI complexes is SNF2H or SNF2L, which are found in 
different complexes with distinct functions. Both NURF and CERF (CECR2- Containing 
Remodeling Factor) complexes contain the SNF2L ATPase. Whereas the NoRC 
(Nucleolar Remodeling Complex) and the WICH (WSTF ISWI Chromatin Remodeling), 
ACF (ATP-Utilizing Chromatin Assembly and Remodeling Factor) and CHARC 
(Chromatin Remodeling by Chromatin Accessibility Complex) complexes contain the 
SNF2H ATPase. Embryos null for BPTF (Bromodomain PHD Finger Transcription 
Factor), the largest NURF complex subunit that is required for complex assembly, did 
not survive beyond the E8.5 days with the absence of DVE and AVE markers. Although 
BPTF null mESCs are viable, they fail to differentiate into endoderm or mesoderm 
(Landry et al., 2008). Knock-out of the remodeling subunit CECR2 in mice also resulted 
in neural tube defects in a strain-specific manner (Banting et al., 2005). Homozygous 
inactivation of the SNF2H resulted in embryo lethality after implantation since SNF2H is 
essential for the survival of ICM and trophoblast cells (Tomas et al., 2003).  
1.3.3 CHD Complexes 
The CHD complexes are classified into three subfamilies: subfamily I (CHD1 and 
CHD2), subfamily II (CHD3 and CHD4) and subfamily III (CHD5, CHD6, CHD7, CHD8 
and CHD9). In mice, Chd1 knock-out is lethal before implantation due to loss of 
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pluripotency. Depletion of CHD1 in bovine embryo reduced the number of blastocysts at 
early developing embryo, with no effect on the pluripotency marker Nanog or the 
trophectoderm marker Cdx2, however it reduced the deposition of the histone variant 
H3.3 (Zhang et al., 2016). The NURD complex consists of CHD3 or CHD4 which is the 
core ATPase subunit, MTA1, 2 or 3 (Metastasis Associated), MBD2 or 3 (Methyl-CpG 
Binding Domain), and RbBP4 or 7 (Retinoblastoma Associated Binding Protein). During 
the assembly of the NURD complex different combination of these mutually exclusive 
subunits are assembled in different cell types (Qin et al., 2001). MBD3, a NURD subunit 
that is required for complex assembly, knock-out resulted in post-implantation lethality 
due to a defective maturation of the ICM into epiblast, and dis-organization of the 
embryonic and extra-embryonic tissues (Kanji et al., 2007). CHD7 is the most studied 
member of this family since the human CHD7 mutations result in CHARGE syndrome, 
which is characterized by severe retardation in growth and development, heart defects, 
coloboma of the eye (abnormal structure of the eye) and ear abnormalities. Some of 
these features are recapitulated in mice with heterozygous loss of CHD7 (Hurd et al., 
2007). 
1.3.4 INO80 Family 
 The INO80 family include the INO80 and SWRI complexes that contain the 
INO80 ATPase subunit. The SWR1 and its homologue in mammals, Tip60/p400, is 
required to deposit the histone variant H2AZ in vivo. H2AZ incorporation is crucial for 
lineage commitment during mESCs differentiation (Creyghton et al., 2008). The INO80 
complex is first identified in yeast where it regulates inositol responsive gene expression 
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(Ebbert et al., 1999). The INO80 subfamily complexes are known to directly regulate 
gene expression in yeast (Shen et al., 2000 and Korbor et al., 2004), mammals (Cai et 
al., 2007), flies (Klymenko et al., 2006) and plants (Deal et al., 2007 and Fritsch et al., 
2004). 
1.4 The INO80 Complex 
The purified INO80 complex is approximately 1.2 MDa in mass and contains 15 
subunits, which include the core catalytic ATPase INO80 subunit, RuvB-like (RuvBL1 or 
RuvBL2), actin (β-Actin) and actin-related proteins (ARP5, ARP8 and BAF53A) (Shen et 
al., 2000). The RvuBL1-2 subunits are homologous to the yeast Rvb1-2 subunits and 
functionally similar to the bacterial DNA helicase RuvB which is involved in DNA DSB 
(double-strand break) repair (Holliday et al., 1974). The actin and ARP (actin-related 
proteins) are required for the INO80 remodeling activity where they bind the HSA 
(helicase-SANT-associated domain) in the ATPase domain (Szerlong et al., 2008). 
Other subunits that are involved in the regulation of specific process, such as YY1 
subunit, which recruits INO80 to target genes to activate their transcription (Cai et al., 
2007). The INO80 complex is involved in many nuclear processes such as DNA 
replication, DNA repair, cell cycle checkpoint and DNA damage response. These 
diverse functions are due to the function of its distinct subunits. The ATPase subunit of 
INO80 is unique because of the presence of a spacer that splits the conserved ATPase 
domain and the deletion of this spacer prevents the assembly of the complex (Yunhe et 
al., 2007). The INO80 ATPase activity is stimulated in vitro in the presence of DNA or 
nucleosomes and this activity enhances nucleosomes sliding or eviction in vivo that 
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subsequently remodel chromatin structure to regulate access to DNA (Tsukuda et al., 
2005). The remodeling activity of INO80 can be modulated by various mechanisms. 
One mechanism is the post-translation modification of the complex subunits. For 
example, upon DNA damage the Ies4p subunit of the yeast INO80 complex is 
phosphorylated by the kinases Tel1p and Mec1p (ATM and ATR in mammals), 
regulators of DNA damage response. However, this modification does not affect the 
complex localization to the DNA damage sites (Morrison et al., 2007). Small signaling 
molecules also modulate the activity of INO80. For instance, the inositol polyphosphate 
kinase Arg82p mediates the recruitment of INO80 to the promoters of phosphate 
responsive genes Pho5 and Pho84 in yeast (Shen et al., 2003). 
1.4.1 INO80 in DNA Damage and Replication 
 To maintain genomic stability, cells have to efficiently repair DNA breaks. NHEJ 
(non-homologous end joining) and HR (homologous recombination) repair DNA DSBs 
(Hoeijmakers et al., 2001). In order for repair proteins to get access to their target DNA, 
chromatin around DNA breaks is remodeled. This remodeling could be accomplished by 
histone modifications, exchange of histone variants and/or ATP-dependent chromatin 
remodeling (Shen et al., 2003 and Loizou et al., 2006). Mouse INO80 is recruited to 
DSBs sites where it is involved in 5’-3’ resection of DNA. It is also, required for the 
loading of the repair protein 53BP1 (p53-binding protein 1). 53BP1 is a DNA damage 
response factor that mediates the repair of DSBs (FitzGerald et al., 2009 and 
Gospodinov et al., 2011). In addition, mouse INO80 is required for the removal of H2AZ  
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from chromatin to facilitate HR of DSBs (Alatwi et al., 2015). The incorporation of H2AZ 
at DSBs restricts strand resection and its depletion reduces the recruitment of 
Ku70/Ku80 complexes to DSBs sites to promote DNA repair (Xu et al., 2012). 
 In mammals, DNA damage induces the phosphorylation of the C-terminal of 
H2AX by ATM into γH2AX, which is crucial component of the DNA damage response. 
Defects in H2AX phosphorylation alter the DNA damage checkpoint and drive genomic 
instability. γH2AX serves as docking sites for DNA repair proteins, such as INO80 
(Nakamura et al., 2004). The mouse INO80 subunit BAF53A (Brg1-Associated Factor 
53a) is associated with γH2AX and upon deletion; it reduces ARP recruitment of INO80 
to DNA damage sites (Downs et al., 2004 and Morrison et al., 2004). In addition, the 
association of γH2AX and INO80 complex at DSB is required for nucleosome eviction 
around the DSB, which facilitates the binding and retention of repair proteins (Wu et al., 
2007 and Morrison et al., 2007). 
 The yeast INO80 subunits Nh10p (non-histone protein 10), Arp4p (actin related 
protein) and Ise3p (Ino80 subunit) have unique roles in association with γH2AX to 
facilitate DNA repair. Mutations in the yeast Arp subunit of INO80 complex results in 
defective DSB repair through homologous recombination or non-homologous end 
joining pathways, which further support its importance in these pathways (Kawashima et 
al., 2007). In response to DNA damage, checkpoint pathways delay the cell cycle until 
DNA is repaired.  
In yeast, Mec1p is a DNA damage checkpoint kinase that activates downstream  
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kinases to arrest the cell cycle, the INO80 subunit Ise4p is one of the Mec1p targets. 
Phosphorylation of Ise4p activates the S-phase checkpoint and delays replication origin 
firing until DNA repair is complete. Once complete then the S-phase checkpoint factor 
Tof1p promotes replication fork recovery to resume the cell cycle (Kattou et al., 2003 
and Tourrie et al., 2005). Similarly, when the replication fork collapses due to DNA 
lesions or due to low levels of nucleotides, Ise4p subunit is phosphorylated to activate 
the S-phase checkpoint to delay the cell cycle progression. Recent studies in yeast 
showed that INO80 is enriched at replication origin, and higher levels of enrichment are 
found at stalled forks, suggesting its role in the recovery of stalled forks during DNA 
replication (Shimada et al., 2008, Papamichos-Chronakis et al., 2008 and Vincent et al., 
2008). 
1.4.2 INO80 and Telomeres, Centromeres and Chromosomes 
  Telomeres are repetitive DNA sequences at the end of the chromosomes, which 
decrease in length at each cycle of replication. Telomeres prevent the recognition of 
chromosome ends as a DSB by DNA repair machinery (d'Adda et al., 2004). The mouse 
INO80 is required for proper telomere replication where it prevents the formation of 
fragile telomeres. In addition, mouse INO80 prevents aberrant recombination between 
telomeres during their replication to prevent the activation of DNA damage response 
(Min et al., 2013). 
 INO80 is required to regulate telomere structure and function. It has been 
reported that deletion of Ies3p, Arp8p and Nhp10p subunits of yeast INO80 increased  
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telomere length indicating their roles in the regulation of telomere structure. In addition, 
the Ies3p subunit deletion induced telomere-telomere fusion events and reduced the 
cells’ growth rate (Yu et al., 2007). During cell division, proper segregation of 
chromosomes is crucial to ensure faithful transmission of genetic material. INO80 has a 
role in chromosome segregation in yeast. The Arp4p and ATPase subunits of Ino80p 
bind directly to centromeres, and mutated Arp4p subunit results in defective kinetochore 
complex formation, and arrest of cell cycle. In addition, deletion of the Arp8 subunit 
increased the rate of sister chromatids separation (Ogiwara et al., 2007). Although the 
exact mechanism of INO80 in the regulation of chromosome segregation is unknown, it 
could be due to its ability to incorporate H2A histone variants into nucleosomes resulting 
in specialized structures with defined roles in centromeres, telomeres, and 
chromosomes. 
1.5 Embryonic Stem Cells 
 Embryonic stem cells are pluripotent cells derived from the ICM before 
implantation, and after implantation they differentiate into the three germ layers of 
endoderm, mesoderm, and ectoderm. The expression of the core pluripotency genes, 
Oct4 (encoded by POU5F1), Sox2 (high mobility group- box transcription factor), Nanog 
(a homeobox transcription factor) and Esrrb are required for the maintenance of ESC 
pluripotency (Nichols et al., 1998, Avillion et al., 2003, Mitsui et al., 2003, Chambers et 
al., 2003 and Martello et al., 2012). The use of LIF (leukemia inhibitory factor) or BMP 
(bone morphogenetic protein) can keep ESCs in a naïve state (metastable state) where  
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they can self-renew. However, these growth conditions result in a heterogeneous 
population of cells with mosaic expression of pluripotency factors (Ying et al., 2003). 
Mechanistically, LIF binds the gp130 on the cell surface, activates STAT3 which then 
homodimerizes, and translocates to the nucleus to activate the transcription of core 
pluripotency genes (Graziano et al., 2013). BMP mediates its signaling through 
phosphorylation of SMAD1, 5, 8 which in turn activates the transcription of Id (inhibitors 
of differentiation) to block differentiation and keep cells pluripotent (Boyer et al., 2005). 
Differentiation mESC results in the secretion of FGF4, which binds the FGF receptor on 
ESC, acting as an autocrine, to activate the MAPK pathway driving differentiation 
(Kunth et al., 2007 and Stavridis et al., 2007). Consequently, the key to maintaining a 
homogenous population of pluripotent cells (the ground state) is to override the FGF4 
differentiation signal and maintain the expression of core pluripotency genes at the 
same time, which is achieved by the use of 2i. 2i blocks the ERK (extracellular regulated 
kinase) to repress differentiation and Gsk3 (glycogen synthase kinase-3) pathways to 
activate pluripotency genes (Ying et al., 2008). The ground state pluripotency mimics 
the pluripotency state of ICM cells. Once LIF or 2i is removed from the media the ESCs 
is reprogrammed to a primed state where the cells are similar to the late epiblast after 
implantation (Nicholas and Smith, 2009). 
 The chromatin organization in mESC has a key role in the switch between 
pluripotency and differentiation states. Pluripotent ESCs have loosely associated 
chromatin architectural proteins such as linker histones and HP1 (heterochromatin  
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protein 1), which results in hyperdynamic chromatin. In addition, staining of the active 
histone marks H3K4me3/ H4K16ac and in situ hybridization of satellite DNA revealed 
less condensed constitutive heterochromatin in pluripotent ESCs (Park et al., 2004 and 
Meshorer et al., 2006). In addition, genome-wide mapping of epigenetic modifications of 
mouse ESCs indicated hypomethylated DNA in those cells (Meissner et al., 2008). 
Although maintaining pluripotency requires an open chromatin state to transcribe 
pluripotency genes, it also requires repression of differentiation genes to keep cells 
pluripotent. The key developmental genes in mESCs are mostly bivalent, which means 
that they have the active histone marker H3K4me3 and the repressive mark H3K27me3 
at opposing H3 tails on the same nucleosome. The bivalency in these genes keeps 
them in a poised state. Once the cells differentiate into a specific cell lineage, bivalent 
genes become monovalent with either activating or repressive marks (Bernstein et al., 
2006).  
 During differentiation, mESCs acquire more condensed, compact and less 
dynamic chromatin structure. Genome-wide analysis of the repressive histone 
modification H3K9me2 identified enrichment of these marks at the facultative 
heterochromatin (gene poor), which constitute 31% of genome in differentiated cells 
compared to 4% in pluripotent ESCs (Wen et al., 2009). In addition, the repressive 
histone mark, H3K27me3, expands into large domain during ESCs differentiation. 
Collectively, ESCs have to repress pluripotency and lineage inappropriate genes and 
activate lineage-specific genes with the help of chromatin modifiers to modulate the 
chromatin architecture according to their needs. Consistently, ESCs express high levels 
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of chromatin remodeling complexes such as BRG1, SNF2H, SSRP1 and SNF5, and 
their disruption resulted in early embryonic lethality suggesting their essential role in 
ESCs gene regulation (Bultman et al., 2000, Klochendler et al., 2000, Cao et al., 2003 
and Stopka et al., 2003). INO80 is required for ESCs self-renewal (Chia et al., 2010; Hu 
et al., 2009), possibly due to its direct role in the regulation of the core pluripotency 
genes to maintain the ESC pluripotency state. In addition, INO80 occupies the 
promoters of pluripotency genes to maintain open chromatin structure and nucleosome 
depleted regions which facilitates the recruitment of RNA Pol II to initiate transcription 
(Li et al., 2014)   
1.6 Mouse Early Development 
 Mammalian development is a very complex process, which starts with a single 
fertilized egg and gives rise to a whole embryo. Upon fertilization, the oocyte mRNA is 
degraded and transcription is initiated from the zygote genome, which is required for 
genetic reprogramming during development, a process known as ZGA (zygote genome 
activation) (Nothias et al., 1995). It has been shown that there is a transient phase of 
ZGA at 2-4 cell stage, which drives the transcription of reprograming genes and another 
phase of maternal genome activation at the 8 cell stage where a peak in transcription of 
adhesion molecules that is required for blastocyst polarity (Hamatani et al., 2004). After 
fertilization, the developmental stages of mouse embryo are determined by the embryo 
age. Embryos are staged by half-day intervals after the detection of a copulation plug, 
and is referred to as E (embryonic day) (Kojima et al., 2014). The fertilized egg 
undergoes three rounds of cell division to reach the eight-cell stage in which the embryo 
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is composed of four blastomeres. At the 8-cell stage, the nucleo-cytoplasmic ratio is 
increased, which induces these blastomeres to compact into a morula. During 
compaction, cells maximize their contact using tight junctions to form a compact ball of 
cells. Compacted cells form a gap junction to allow the passage of small molecules and 
ions for their nutrition (Fleming et al., 1992, Ducibella et al., 1975 and ziomek et al., 
1980). Compaction establishes apical-basal polarity in the morula by asymmetrical 
loading the cellular polarity proteins such as PKC (protein kinase C), PAR3 and PAR6 
(Pauken and Capco, 2000; Plusa et al., 2005) to the apical cells of the morula. However 
proteins such as Par1 (protease activator receptor 1) and E-cadherin (Hyafil et al., 
1980; Shirayoshi  et al., 2005) localize to the basolateral side of the morula by E2.5. 
Compacted morula undergoes two successive rounds of asymmetric cell division to 
form 16-32 blastocyst embryo.  
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Figure 1.2: Cartoon to Illustrate Stages in the Early Mouse Development. 
The morphological changes and the cell specification events that occur from fertilization to embryonic day 
E7.0. The morula stage at E2.5, the blastocyst stage at E3.5, and the gastrula stage at E6.5. The pre-
gastrula stage starts at E5.5 where a subset of PrE cells differentiate at the distal part of the embryo to 
form DVE. From E5.5 to E6.5 these cells migrate to the anterior part of the embryo to form AVE. During 
this transition the AVE secretes inhibitors to the Wnt and TGF family of ligands, directing gastrulation at 
the posterior of the embryo. http://www.devbio.biology.gatech.edu/?page_id=8796. 
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 A blastocyst is formed at E3.5 by cavitation; formation of a single cavity; and 
allocation of three cell lineages which include TrE (trophectoderm), PrE (primitive 
endoderm) and EPI (epiblast) as illustrated in Figure 1.2. TrE is the outer layer of cells 
that contact the LE (luminal epithelium) of the uterus to establish the site of 
implantation. TrE will form the chorion (abembryonic tissue), which is required for 
embryo nutrition and immunity at implantation site (Pedersen et al., 1987). The ICM is 
composed of pluripotent cells that will form the embryo proper (embryonic tissue). The 
segregation between these three different cell lineages (TrE, PrE and EPI) is defined by 
the expression of specific genes for each lineage. Oct4, Sox2, Nanog and Nodal genes 
are required for the formation and maintenance of the ICM, suppression of TrE 
formation and specification (Nichols et al., 1998, Avillion et al., 2003, Mitsui et al., 2003, 
Chambers et al., 2003 and Camus et al., 2006). TrE specification was thought to be due 
to the absence of Oct4 expression, however Strumpf et al. showed that the Cdx2 (a 
caudal type-homeodomain protein) is essential for TrE specification and its absence 
extends the expression domain of Oct4 and Nanog into the outer layer (Strumpf et al., 
2005). In addition, the T-box transcription factor, Eomes, is required for TrE cells 
proliferation (Russ et al., 2000). Similarly, PrE is specified by the expression of Gata6, 
which suppress the expression of Nanog (Mitsui et al., 2003 and Chambers et al., 
2003). 
  In addition, epigenetic changes like histone modifications are key players in the 
molecular definition of these cell fates. For example, the levels of active histone 
markers, H4K8ac and H3K4me3, at the promoter region of Oct3/4 are higher in the 
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ICM cells than in the TrE cells (VerMilyea et al., 2009). The behavior of these factors 
inside the cell also affect those cells fate. Monitoring the kinetics of Oct3/4 nuclear 
export, import and retentions revealed that Oct3/4 accessibility to its targets differ 
between four- and eight- cell stage (Plachta et al., 2011).  
The embryonic-abembryonic axis specification is similar to the P-D (proximal-
distal) axis of the embryo at the egg cylinder stage, which will determine the future 
dorsal-ventral polarity (Rossant and Tam, 2009). In addition, the inside-outside polarity 
of the blastocyst is also accompanied by differential asymmetric signaling of Hippo 
pathway in those parts of the blastocyst. Hippo signaling control cell contact-mediated 
inhibition of ICM proliferation. However, it is not active in the outer cell layer where the 
apical part of these cells is not in contact with other cells (Pan, 2007; Saucedo and 
Edgar, 2007). The peri-implantation blastocyst exhibits additional asymmetries, for 
example, the nuclear β-catenin is localized to a subset of blastomeres and Nodal is 
localized to another subset suggesting asymmetry at the level of canonical Wnt and 
Nodal signaling (Chazaud et al., 2006 and Granier et al., 2011). 
 In order for the blastocyst to implant, it has to be competent for implantation in 
the receptive uterus. Many factors affect blastocyst competency, for instance, cate-
choloestrogens, endocannabinoid and anandamide are signaling molecules secreted in 
the uterus to activate the blastocyst (Paria et al., 1998 and Guo et al., 2005). The 
implantation process is divided into three stages; apposition, adhesion and penetration. 
Apposition, where TrE of the blastocyst closely oppose the LE of the uterus to prevent 
blastocyst dislodging (Daikoku et al., 2005). Once the blastocyst opposes the LE it 
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attaches by help of adhesion molecules such as integrin (Dey et al., 2004). After the 
blastocyst attaches, penetration occurs at the site of implantation to increase the 
vascular permeability by the action of prostaglandin (Lim et al., 1997). After 
implantation, the stromal cells of the uterus that envelop the blastocyst undergo 
decasualization to nourish the embryo and form the placenta, which is accompanied by 
increased angiogenesis (Matsumoto et al., 2002). Once the blastocyst is implanted, it 
develops into a cylindrical structure called the egg cylinder, which will undergo 
gastrulation (Patrick et al., 1997). 
1.7 Gastrulation  
  Gastrulation is a blueprint for body plan determination and subsequent 
morphogenesis. Immediately after implantation (approximately at E5-6), the embryo 
mass is increased by about 40 fold mainly due to increased cell proliferation and 
reduced apoptosis rates. At this stage, an epithelization of ICM cells into a single cell 
layer surrounding the amniotic cavity forming a cup-shaped embryo (in the case of 
rodents), where the cup has two cell layers, the outer VE (visceral endoderm) and inner 
Epi (epiblast), forming an egg cylinder with two cell layers. The egg cylinder embryo has 
well defined extra-embryonic and embryonic regions that are polarized to P-D body 
axis. During gastrulation, a series of morphogenetic movements results in the formation 
of three germ layers: ectoderm, endoderm and mesoderm. The mouse gastrulation is 
accomplished by the differentiation, delamination, and migration of underlying 
embryonic ectoderm into the primitive streak to establish the A-P (anterior-posterior) 
axis of the embryo (Patrick et al., 1997). 
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 As mentioned earlier PrE is the epithelial layer that surrounds the blastocoelic 
cavity. At E5.5, this layer forms the VE that surrounds the epiblast and parietal VE that 
surround the TrE. A subset of distal VE cells differentiates into DVE at E5.5 (Rossant 
and Tam, 2009; Takaoka and Hamada, 2012). DVE cells express both Nodal and Wnt 
antagonists, which are Lefty1, Cer1 and Dkk1 consequently (Yamamoto et al., 2004 and 
Kimura-modisha et al., 2005). Restriction of Lefty1 expression to a subset of PrE cells 
could be regulated by three mechanisms: (1) Lefty1 is regulated directly by Nodal 
through Nodal/FoxH1 responsive enhancer upstream of Lefty1. (2) Nuclear β-catenin is 
localized to Epi cells that face PrE suggesting that Wnt signaling activates Nodal which 
in turn regulate Lefty1 expression (Chazaud and Rossant 2006). (3) Establishment of P-
D axis is maintained by asymmetric expression of signaling molecules and asymmetric 
expression of Nodal restricts Lefty1 expression to a subset of PrE cells (Granier et al., 
2011). 
 From E4.5 to E5.5 the expression of Lefty1 is auto-regulated by Lefty1 itself 
(Christopher et al., 2001). At E5.5, DVE cells mature and express other DVE markers 
such as Cer1 and Hex1. The restriction of DVE cells to the distal part of the embryo is 
maintained by inhibitory BMP signaling. Bmp4 expression in the extraembryonic 
ectoderm generates a signaling gradient that allows DVE differentiation only at the distal 
part of the egg cylinder. This was further supported by the observation that ExE deletion 
resulted in DVE expansion (Roriguez et al., 2005 and Yamamoto et al., 2009). After the 
DVE matures, the VE cells get thicker and create a monolayer of tall-columnar cells 
(Takaoko et al., 2011), then DVE cells form a lamellopodia-filopodia like structure that 
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migrates to the anterior part of the embryo to establish the AVE and the A-P axis 
(Migeotte et al., 2010).  
 How the complicated process of animal embryonic development is regulated by 
epigenetics is just beginning to be unraveled. ATP-dependent chromatin remodeling 
complexes are essential for mammalian development where they regulate specific 
developmental pathways (Ho et al., 2010 and Chen et al., 2014). The chromatin 
remodeling complexes, NURD (Kaji et al., 2007), SWI/SNF (Bultman et al., 2000), and 
TIP60/p400 (Thomas et al., 2008) complexes are essential for pre-implantation 
development.  While, other complexes including NURF (Landry et al., 2008) and CHD7 
(Hurd et al., 2007) are involved in post-implantation development. Mammalian INO80 is 
also essential for development. Genome-wide siRNA screening show that Ino80 is 
required for ESC self-renewal by promoting the expression of pluripotency genes such 
as Oct4 and maintaining an open chromatin structure around pluripotency factors (Li et 
al., 2014). In vivo, Ino80 KO mouse embryos implant but fail to develop to mid-gestation 
(Min et al., 2013), possibly due to abnormal gene expression because INO80 is well-
known to regulate gene expression (Li et al., 2014). However, the exact mechanism by 
which INO80 regulates early mouse development is unknown. The purpose of this study 
is to characterize the role of the INO80 chromatin-remodeling factor in early mouse 
embryo, and identify the mechanisms by which it regulates development. 
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CHAPTER TWO 
 
Methods 
 
 
2.1 Generation of Conditional Ino80 KO Mice.  
 This was done according to the standard protocol. The Animal Care and Use 
Committee of Virginia Commonwealth University approved all experiments and animal 
procedures under protocol AD10000372 and its modifications (Bouabe et al., 2013). 
2.2 DNA Extraction & Genotyping 
 DNA was extracted from embryos for genotyping by digesting individual embryos 
overnight at 55°C in 10 to 20 µl PBS (phosphate-buffered saline) (10 mM Na2HPO4, 
and 1.8 mM KH2PO4 [pH 7.4], 137 mM NaCl, 1.37 mM KCl), 0.1% tween 20 and 0.2 
mg/ml PCR grade proteinase K (Roche). After digestion, proteinase K was heat 
inactivated at 100 °C for 15 min and 2 µl of digested embryo was used for PCR 
genotyping. Genomic DNA was extracted from tail biopsies or cells by overnight 
digestion in lysis buffer (50 mM Tris-Cl [pH 8.0], 100 mM EDTA, 100 mM NaCl and 1% 
SDS) containing proteinase K (0.5 mg/mL) at 53 °C. Following digestion, DNA was 
precipitated with isopropanol, washed with 70% ethanol and dissolved in water. The 
genotyping of Ino80 was done using primers P1, P2, and P3 in a multiplex PCR reaction 
using recombinant Taq polymerase with Thermal Pol Buffer (NEB). PCR conditions 
were as follows: 94 °C for three minutes (min) for one cycle, 94 °C for 30 secs, 54 °C for 
60 secs, 72 °C for 45 sec repeated for 40 cycles. Primer sequences are provided in 
Table 2. 
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Table 2.1: Primers Used for Ino80 Genotyping 
 
Ino80 Genotyping Primers  
P1 CTGGATGTGAAGGGAGAAGG 
P2 CATCTCTCCAGCCAGCACACT 
P3 TGCCACTCTACCTGCATCTG 
 
2.3 Embryonic Cells Isolation and Maintenance 
 To generate Ino80 KO ESCs, E2.5-day blastocysts were harvested in KSOM 
media until the blastocyst stage then induced to hatch in the presence of Tyrodes 
solution (Sigma T1788). Blastocysts were cultured on gelatinized plates for seven days 
in defined 2i + LIF media without serum (Millipore Cat# SF016-100). Individual 
outgrowths were removed by scratching from plate bottom with a fine glass pipette, 
dispersed into single cells with 0.25 % trypsin + EDTA, cultured in gelatinized 96 well 
plates in the presence of 15 % ESC grade FCS (Life Technologies) and 2i medium 
formulation (Life Technologies). 
 Primary MEFs were isolated from mouse pregnant females at E13-14. Mouse 
female was sacrificed by cervical dislocation and individual embryos were isolated from 
the uterine horns under aseptic conditions. Head and internal organs were removed and 
the embryo body was finely minced until it can be pipetted. Digested embryo was 
treated with 0.25% trypsin/EDTA in the presence of 100 K units of DNase I (USB) for 15 
min at 37°C to obtain single cell suspension. Trypsin was inactivated by MEF culture 
medium (DMEM containing 10% FCS, 2 mM glutamine, 1 mM nonessential amino 
acids, penicillin, and streptomycin). Cells were then centrifuged, suspended in MEF 
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culture medium and plated on gelatinized plates. MEFs were treated with 10 ng/ml 
doxycycline in MEF culture  
medium to knock-out Ino80. After two days of treatment, the medium was replaced with 
fresh medium and MEFs were cultured until subconfluency. Ino80 deletion was verified 
by PCR.   
2.4 Detection of MEFs Senescence by Lac-Z Staining 
 To measure β-galactosidase activity, MEFs were fixed in 4% buffered 
formaldehyde for five   min, washed and stained with staining solution (35 mM 
potassium ferrocyanide, 35 mM potassium ferricyanide, 0.02% NP-40 and 2 mM MgCl2 
[pH 6]) overnight with gentle rocking. Stained cells were washed and positively stained 
cells were counted using a microscope. 
2.5 Alkaline Phosphatase Staining 
AP activity was analyzed using the BM purple AP substrate (Roche Cat# 
11442074001), according to the manufacturer’s guidelines. Cell colonies were fixed 
in 0.2% glutaraldehyde, 0.02% NP-40, and 0.01% sodium DOC for five min followed by 
washing in 100 mM Tris-HCl [pH 9.5], 100 mM NaCl and 10 mM MgCl2. Colonies were 
stained, washed, air dried and examined under light microscope.  
2.6 Cell Doubling Time 
 To determine the doubling time, mESCs were  plated in triplicates in 12 well 
plates. Cells were counted using a hemocytometer at time points 24, 48, 72, and 96 
hours. I took the average cell count from each of the big four squares. and multiply by 
10,000  then multiply by 2 to correct for trypan blue addition Population doubling times 
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were calculated using http://www.doubling-time.com.These measurements were 
repeated for three independent control and Ino80 KO mESCs. 
2.7 Teratoma and Embryoid Body Formation 
 Teratomas was generated by injection of 1 × 106 ESC into the flank of 
NOD/SCID mice (Jackson Labs Cat# 001303). Three weeks later teratomas were 
collected, embedded in OCT medium and frozen in liquid nitrogen. Teratomas were 
sectioned using a cryostat and sections were fixed in 10% neutral buffered formalin, 
stained with hematoxylin and eosin, and analyzed by light microscopy. 
 To create embryoid bodies 10 × 106 ESC were suspended in 13 × 100 mm 
polypropylene culture tubes. The cells were supplemented with 3 ml of complete ESC 
medium without addition of LIF or 2i to promote cells differentiation. Embryoid bodies 
were harvested at the indicated time points. For histological analysis, embryoid bodies 
were collected at day 9 and fixed in 10% neutral buffered formalin overnight, then 
embedded in OCT medium and frozen in liquid nitrogen.  Sections were obtained by 
cryostat sectioning, stained with hematoxylin and eosin, and analyzed by light 
microscopy. 
2.8 Whole Mount in Situ Hybridization 
 Embryos were collected at the indicated time points in PBS, fixed in 4% 
paraformaldehyde for 5 min.  Fixed embryos were then dehydrated through a series 
of methanol (25%, 50%, 75%, and twice in 100%) and kept in 100% in methanol at 
−20°C until use. To prepare embryos for in situ hybridization they were rehydrated 
through 75%, 50%, and 25% methanol series then fixed again in 4% and 0.2%  
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glutaraldehyde in PBS-T (Phosphate-buffered saline 0.1% tween 20). To start 
hybridization, embryos were washed three times in PBS-T and mixed with pre-
hybridization buffer (25ml formamide, 12.5 ml 20X SSC, 5ml 10% SDS and 7.3ml 
DEPC treated water) at 70°C for 1 hr. Hybridization buffer was then replaced with 
one ml of the same buffer mixed with ~ 1µg of DIG (Digoxigenin)-labeled probe and 
then incubated overnight at 70°C. Embryos were washed twice for 30 min using 
solution I (50% formamide, 4XSSC and 1% SDS) followed by 10 min wash in 1:1 
solution I: solution II (500 mM NaCl, 10 mM Tris [pH 7.5] and 0.1% tween 20). 
Embryos were then washed three times 5 min each in solution ll at room 
temperature and incubated with solution II mixed with 100 µg/ml RNase at 37°C for 
1 hr followed by one wash in solution ll and another wash in solution lll (50% 
formamide and 2XSSC). Embryos were then washed twice for 30 min each with 
solution lll at room temperature. Then washed three times for 5 min each with 
MABTL (100 mM maleic acid [pH 7.5], 150 mM NaCl, and 0.1 % tween 20 and 2 
mM levamisole). To prevent non-specific staining embryos were incubated with 10% 
heat-inactivated sheep serum, 2% BMBR (Boehringer Mannheim Blocking Reagent) 
in MABT for 3 hrs. During the incubation period, anti-digoxygenin-AP (Roche) was 
mixed with 3 mg embryo powder, 2% BMBR and 10 µl of sheep serum in 1 ml of 
MABTL and rotated at 4°C for 3 hrs. Embryos were then incubated with the diluted 
antibody at 4°C overnight. Embryos were then washed for 5-8 times 1 hr each with 
MABTL and the color was developed with BM purple (Roche) after three washes 
with NTMTL buffer (100 mM Tris, [pH 9.5], 100 mM NaCl, 50 mM MgCl2, 0.1 %  
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tween 20 and 2 mM levamisole). For double ISH DIG-Bmp4 and FITC-Otx2, labeled 
probes were detected by AP-conjugated anti-DIG Fab, which was detected by BM 
purple (Roche) and anti-FITC Fab fragment, which is detected by INT/BCIP (Roche), 
subsequently. 
2.9 TUNEL Assay 
 Programmed cell death is characterized by DNA fragmentation, which can be 
quantified by the ability of the terminal deoxynucleotidyl transferase enzyme to 
incorporate labeled nucleotides to the 3’ hydroxyl of fragmented DNA. To quantify 
apoptosis, we applied whole-mount tunnel staining procedure. Briefly, E6.5 embryos 
were fixed for 2 hrs at 4°C, washed with PBS-T and kept in 100% a methanol until use. 
Fixed embryos were then treated with 5:1 methanol: 30% hydrogen peroxide for three 
hours to reduce endogenous peroxidase activity. Then, they were washed in a methanol 
and treated with 20 µg/µl proteinase K for 3 min to digest proteins and facilitate the 
enzymatic addition of labeled nucleotides. After proteinase K treatment, embryos were 
fixed with 0.2% glutaraldehyde in 4% paraformaldehyde for 20 min at room 
temperature, washed three times with PBS-T and treated with sodium borohydride for 
20 min to remove reactive aldehydes. Embryos were then washed with TdT buffer (30 
mM Tris-HCl [pH 6.6], 200 mM potassium cacodylate, and 2.5 mM CoCl2). TdT buffer 
was replaced with labeling solution that contain 9:1: labeling solution (nucleotide 
mixture): enzyme (terminal deoxynucleotidyl transferase) and incubated at 37°C for 2 
hrs. Then embryos were rinsed several times with PBST and incubated at 70°C with the 
labeling solution for another 20 min. To block non-specific binding, embryos were  
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treated with 10% heat- inactivated sheep serum at room temperature for 1 hr and then 
incubated with the converter-POD (anti-fluorescein antibody, Fab fragment from sheep, 
conjugated with horseradish peroxidase) at 37°C for 30 min followed by washing and 
color development using the DAB substrate. Samples were analyzed using fluorescent 
microscope and percent of apoptotic cells were normalized to the total number of DAPI 
positive nuclei in a 50-µm microscopic field. 
2.10 Chromatin Immunoprecipitation (ChIP)  
mESCs cells were induced to differentiate by culture in complete ESCs medium 
that lack both LIF and 2i. Cells were collected at the indicated time points and fixed in 
1% PFA in PBS for 15 min. To remove the fixative, cells were washed three times in 
PBS and scrapped from the tissue culture dish by a cell scraper. Cells were suspended 
in lysis buffer and protease inhibitor and the chromatin was fragmented by sonication, 
using Bioruptor sonicator set at 15% amplitude for three sessions of 45 pulses (0.5 
second on/0.5 second off), incubating the sample on ice for two min between sessions 
to fragment DNA to ~ 500bp fragments. After sonication, the cell suspension was 
centrifuged at 13,000 rpm for 10-20 min at 4°C. The supernatant was diluted at 5:1 by 
ChIP dilution buffer (16.7 mM Tris-HCl [pH 8.1], 167 mM NaCl, 1.1% triton X-100, 1.2 
mM EDTA and 1 X protease inhibitor cocktail (Roche) then mixed overnight at 4°C with 
protein G Dynal beads (Life Technologies) pre-bound for 1 hr at 4°C with antibody (10 μl 
of beads with 5 μg antibody). For each pull-down, 20% input was saved for 
determination of pull-down efficiency using qPCR. The following antibodies were used 
for ChIP: Ino80 (VCU23, custom rabbit polyclonal), SP1 (Santa Cruz Biotech # sc-59),  
  
  
    
  
 
36 
 
pan-histone H3 (Abcam # ab1791), and H3K4me3 (Abcam # ab1012) and anti-BPTF 
(Millipore ABE1966). After overnight incubation, bound chromatin was subjected to a 
series of 5 washes (5 min each) on ice using the following buffers; low-salt buffer (20 
mM Tris [pH 8.0], 150 mM NaCl, 1% triton X-100, and 2 mM EDTA), high-salt buffer (20 
mM Tris [pH 8.0], 500 mM NaCl, 1% triton X-100, and 2 mM EDTA), LiCl buffer (10 mM 
Tris [pH 8.0], 0.25 M LiCl, 1% NP-40, 1% deoxycholic acid, and 1 mM EDTA) and two 
times with TE buffer (10 mM Tris [pH 8.0], 1 mM EDTA). The DNA was eluted from the 
beads by two washes with 250 µl elution buffer (0.1 M NaHCO3, and 1% SDS) at room 
temperature. Both eluted DNA and the 20% input DNA were reverse cross-linked with 
200 mM NaCl and incubated overnight at 65°C. Next, samples were treated with 
proteinase K for 4 hrs at 45°C.  The DNA was extracted using phenol-chloroform 
extraction, precipitated with ethanol and dissolved in water treated with RNase A and 
then quantified by qRT-PCR. The sequence for primers used for ChIP-PCR are 
provided in Table 2.2 
Table 2.2: Primers Used for Bmp4 ChIP Analysis 
 
 
 
 
 
 
 
 
Bmp4 ChIP Primers 
Amplicon1 For  GTGCCCAAAGCATTTTGAAT 
 Rev CACCCTACTTCCACCTCCAA 
Amplicon2 For  CCAGTGCTCTCTCACCTTCC 
 Rev CAGGGGAGGTCACGAAGATA 
Amplicon3 For  TACAAACGAGGATGGGGAAG 
 Rev CCAAGAACCGGAAATTGCTA 
Amplicon4 For  CCCAATGACCTCTCTTCCAA 
  Rev TTGGCCTATTCCTCCTTCCT 
Amplicon5 For  ATGGCATGGTTGGTTGAGTT 
  Rev ACGTAGTCCCAAGCATCACC 
Amplicon6 For  ATGACCGGGTTGAAAGATTG 
  Rev GAAAGCCACACCTCCTTCTG 
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2.11 Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE) 
 Positive regulatory factors enhance nucleosomes eviction at their target DNA 
sequences. The idea of the FAIRE technique is to identify nucleosome-depleted DNA 
sequences (open chromatin). FAIRE is a simple technique to identify nucleosomes 
depleted DNA sequences and it is superior to DNase I hypersensitivity assay. The idea 
behind FAIRE technology is the crosslinking of proteins to DNA, fragmentation of the 
chromatin and enrichment of nucleosome depleted DNA sequences by phenol-
chloroform extraction. To identify the chromatin status at Bmp4 promoter in both WT 
and Ino80 KO cells we applied the FAIRE technique. Briefly, cells were fixed in 1% 
paraformaldehyde and resuspended in FAIRE lysis buffer (50 mM Tris [pH 8.0], 1% 
SDS, 10 mM EDTA). Protein degradation was inhibited by addition of 1X protease 
inhibitor cocktail (Roche) to the lysis buffer. Samples were sonicated as indicated above 
and sonicated samples were centrifuged at 15,000 rpm at 4°C to remove cell debris. An 
equal volume of supernatant and phenol-chloroform were mixed, vortexed and 
centrifuged at 15,000 rpm to isolate FAIRE DNA in the aqueous phase. FAIRE DNA 
was ethanol precipitated in the presence of 0.3M sodium acetate and dissolved in TE 
buffer (10 mM Tris-HCl [pH 7.4], 0.5 mM EDTA). Dissolved DNA was treated with 
RNase at 100 µg/ml for 30 min at 37°C followed by proteinase K treatment at 55°C for 1 
hr. After removal of residual RNA and proteins, FAIRE DNA was washed, mixed with 
DNA binding buffer at 2:1 ratio then purified using Zymo-I spin columns (Zymo  
research). The input DNA was prepared from the soluble chromatin after sonication 
where 50 µl of soluble chromatin was treated with RNase and proteinase K, as  
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described above, and cross-linked between DNA molecules was reversed by keeping 
samples at 65°C overnight. DNA was extracted by phenol-chloroform extraction 
followed by ethanol precipitation. Enrichment of individual loci was quantified by qRT-
PCR. Primers were designed to amplify a control region that has similar enrichment in 
both WT and Ino80 KO samples and a reference region that has different enrichment. 
Relative enrichment was quantified and calculated using the ∆∆CT method (Livak et al., 
2001). Primer sequences are provided in Table 2.3. 
Table 2.3: Primers Used for FAIRE Analysis 
Bmp4 promoter FAIRE Primers 
Amplicon1 For CTTCCCTCCTCCCTTAATCG 
 Rev1 GTGGCTGGATGGGAGGAT 
Amplicon 2 For1 GTTGAAACAGGCTGTGAGCA 
 Rev1 GGGGGAAAGTCACCTCCTAA 
Amplicon 3 For1 AATTTCACACCCTGCCTCTG 
 Rev1 TTCCCCATCCTCGTTTGTAA 
Amplicon 4  For1 GATTGATTCCCTGCGTCACT 
 Rev1 TCAGTCATTTTCGGTCTGG 
Amplicon 5 For1 CAGGTAGAGTGGTGCATGCTT 
 Rev1 GATCATCTGGCTGCCTCTGT 
Control Primers For1 ATACAACCAAACAGACACACAACC 
 Rev2 CTACTGGCTGCCATGGCTTA 
 
2.12 qRT- PCR  
 RNA was extracted from ESCs and embryoid bodies using Tri-Reagent (Sigma) 
according to manufacturer’s instructions. 5 µg of isolated RNA was converted into cDNA 
using the reverse transcriptase Superscript II according to manufactures procedures  
(Life Technologies). cDNA was diluted and amplified using SsoAdvanced universal 
SYBR green supermix (Biorad) in 20 µl reaction that contains 300 nM of both forward  
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and reverse primers. Reactions were heated for 15 min at 95 °C, then cycled for 50 
cycles at 95 °C, 30 secs, 60 °C 30 secs and 72°C 30 sec. Relative expression of target 
templates was normalized to GAPDH using the ∆∆CT method (Livak et al., 2001). 
Primers sequences are provided in Table 2.4. 
Table 2.4: Primers Used for Quantification of Pluripotency and Differentiation 
Markers in   mESCs 
 
qRT‐PCR Primers  
INO80  For CGAGGGAGCGAGCTAGGAG 
 Rev TCAACTTGGCTTTAAGCTTCTTG 
Nanog For AGGGTCTGCTACTGAGATGCTCTG 
 Rev CAACCACTGGTTTTTCTGCCACCG 
Oct4 For TGAGGCTACAGGACACCTTTC 
 Rev GTGCCAAAGTGGGGACCT 
Klf4 For GCGAGTCTGACATGGCTGT 
 Rev GAGTTCCTCACGCCAACG 
Essrb For CGATTCATGAAATGCCTCAA 
 Rev CCTCCTCGAACTCGGTCA 
Sox2 For TGCTGCCTCTTTAAGACTAGGG 
 Rev TCGGGCTCCAAACTTCTCT 
c-myc For CACCAGCAGCGACTCTGAA 
 Rev CCCGACTCCGACCTCTTG 
n-myc For AACACAGCGCTTGAGGATCA 
 Rev GAGCGACTCAGATGATGAGGA 
Cdx2 For GGAAGCCAAGTGAAAACCAG 
 Rev CTTGGCTCTGCGGTTCTG 
Bmp4 For CTGAGTATCTGGTCTCCGTCC 
 Rev AAGGCTCAGAGAAGCTGCGGC 
Fgf5 For CAGATCTACCCGGATGGCAAAG 
 Rev GCGGACGCATAGGTATTATAGCTG 
Nestin For ACCTCAAGATGTCCCTTAGTCTGG 
 Rev GGTGCTGGTCCTCTGGTATCC 
Nodal For GGGCCCACTCACCATTGACA 
 Rev TCCTGAGGCCGGTTGGAGTA 
T For TGAGGAGATTACAGCCCTTAAA 
 Rev GGTTCCTTAGAGCTGGGTAC 
Wnt3 For GGGGCGTATTCAAGTAGCTG 
 Rev GTAGGGACCTCCCATTGGAT 
Gsc For CGGTTCTGTACTGGTGTCTCCT 
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 Rev GAGCTGCTCATCGGTCAAGAT 
Fgf8 For TCATTGTGGAGACCGATACTT 
 Rev CAGCACGATCTCTGTGAATAC 
Foxa2 For GCCAGCGAGTTAAAGTATGCG 
 Rev TGTTGCTCACGGAAGAGTAG 
Sox17 For CCATTTAGTGAAGAAACTGAAATATGGC 
 Rev ATTCTCTTGATAGATACTTTGGGAGGAGT 
Gata4 For AGGTAGTGTCCCGTCCCATCT 
 Rev CCTGGAAGACACCCCAATCTC 
Gata6 For AGTCAAAAGCTTGCTCCGGTA 
 Rev ACCTATGTAGAGGCCGTCTTGA 
Hex1 For GAGGTTCTCCAACGACCAGA 
 Rev GTCCAACGCATCCTTTTTGT 
Cer1 For CACGAAGTACACTGGGAGAC 
 Rev GCCAAAGCAAAGGTTGTTCT 
Hnf4a For CTTCCTTCTTCATGCCAG 
 Rev ACACGTCCCCATCTGAAG 
 
2.13 Statistics 
 The standard deviation was used to calculate error bars throughout the study. P 
values were calculated using two tailed T-tests. The number of replicates are 
designated in the figure legends. 
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CHAPTER THREE 
 
Results 
3.1 Ino80 KO Embryos Fail to Develop After Implantation 
Ino80 deletion is known to be embryonically lethal (Min et al., 2013 and Lee et 
al., 2014), however, its exact role in early mouse development is not identified. To 
investigate the role of Ino80 in mouse early embryo, we used the Cre-loxP system in 
which the essential exons of Ino80 were flanked by two loxP sites that were excised 
after crossing with mice that express Cre recombinase. Successful Ino80 KO was 
verified in both Ino80 KO MEFs using Western blot analysis (Figure 3.1 A). At the 
cellular level, Ino80 KO in MEFs reduces cell proliferation and induces senescence (Min 
et al., 2014). To verify this observation using our model of Ino80 KO in MEFs, we 
assessed the proliferation rate of Ino80 floxed MEFs for about 12 days after their 
exposure to doxycycline in culture (Figure 3.1 B). As shown previously, Ino80 KO MEFs 
ceased proliferation and started senescence as evidenced by their positive staining for 
β-Gal activity (Figure 3.1 C). These data suggested that our Ino80 KO allele is a null 
allele. 
To characterize the phenotypes of Ino80 KO in mouse embryo we inter-crossed 
heterozygous mice to generate homozygous Ino80 KO mice. However, we did not get 
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any homozygous KO mice, consistent with previous studies that showed that Ino80 is 
essential for mouse embryo viability (Min et al., 2013 and Lee et al., 2014). To identify 
at which stage Ino80 is essential for embryo viability, we collected mouse embryos at 
different stages of early development E5.5 (post-implantation), E6.5 (gastrulation) and 
E13.5 (mid-gestation). Genotyping of these litters revealed that Ino80 KO embryos fail 
to survive after implantation. Phenotype analysis of E5.5, E6.5 and E7.5 embryos 
indicated that at E5.5 both WT and KO embryos had similar size and morphology, 
however, once they implanted Ino80 KO embryos started to decrease in size and lose 
their structural integrity by E7.5 (Figure 3.1 D, and data not shown). These observations 
suggesting that Ino80 KO embryos fail to develop after implantation. 
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Figure 3.1:  Ino80 is Crucial for Mouse Embryonic Fibroblast Survival and Early Embryonic               
Development. 
A) Western blot analysis of Ino80 protein expression in wild type and Ino80 KO ESCs. 
B) Growth rate of conditional Ino80 KO MEF induced by doxycycline treatment. 
C) -galactosidase activity of Ino80 KO and WT MEFs at day 12 of culture, 
Black arrows indicate -galactosidase positive cells. 
D) Microscopic Comparison of E5.5-, E6.5-, and E7.5-day wild-type and homozygous Ino80 KO 
embryo. For all experiments, N ≥3. * = t-test p-value ≤0.05. 
This figure is done by Dr. Zhijun Qui. 
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3.2 Ino80 KO Embryonic Stem Cells Are Viable and Pluripotent only in the 
Presence of 2i 
To characterize the effect of Ino80 KO on early embryo development further, we 
isolated mESCs from pre-implanted blastocysts at E3.5 after heterozygous inter-
crossing. In order to maintain mESCs in culture, we have to use medium that maintains 
ESC self-renewal and pluripotency. We cultured both WT and KO blastocysts on 
gelatin-coated plates and culture media supplemented with LIF (Leukemia Inhibitory 
Factor) and 2i. Both WT and KO blastocysts outgrew and we successfully isolated 
mESCs from these outgrowths and maintained them at ground state pluripotency 
(homogenous population of pluripotent mESCs) by addition of 2i to the media in the 
presence of LIF (Figure 3.2 A). Under these conditions both WT and KO mESCs 
proliferate at similar rates and stained equally for alkaline phosphatase, a marker of 
pluripotency (Figure 3.2 B). However, upon 2i withdrawal from the media, Ino80 KO 
mESCs started to scatter and differentiate suggesting that Ino80 is required to maintain 
a metastable pluripotency state (Figure 3.2 C). 
 Moreover, the proliferation rate of Ino80 KO mESCs was lower than that of WT 
cells even in the presence of 2i (Figure 3.2 D). Pluripotency and differentiation markers 
of WT and Ino80 KO mESCs were quantified by qRT-PCR at different culture conditions 
(Figure 2 E&F). qRT-PCR data analysis revealed that at ground state pluripotency. 
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Ino80 KO ESCs express similar levels of pluripotency markers Nanog, Oct4, Klf4, Sox2, 
and Essrb compared to WT cell Esrrb is a down-stream target in the GSK3/Tcf3  
pathway and it is critical for modulating ESCs self-renewal (Martello et al., 2012). Both 
C-myc and N-myc are required for pluripotency and self-renewal of ESCs(Varlakhanova 
et al., 2010). Nanog, Oct4 and Sox2 are the core pluripotency markers, which are 
interconnected by autoregulation loop (Boyer et al., 2005). In addition, the levels of 
ectoderm, mesoderm, and endoderm markers were approximately equivalent in both 
WT and Ino80 KO mESCs. In contrast, the levels of the respective pluripotency markers 
are reduced in Ino80 KO mESCs under metastable pluripotency state (heterogeneous 
population of pluripotent mESCs) (Figure 3.2 E). Based on the above results, Ino80 is 
required for metastable state but not ground state pluripotency of mESCs. 
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Figure 3.2: Ino80 KO ESC Are Viable and Pluripotent only in the Presence of 2i in the Culture 
Medium. 
A)Microscopic analysis of wild type and Ino80 KO pre-implantation E3.5 blastocysts.  
B) The morphology of wild type and Ino80 KO ESCs grown in the presence of serum+2i+LIF or 
serum+LIF.  
C) Comparison of Alkaline phosphatase activity in wild-type and Ino80 KO ESCs after plating at in media   
containing serum+2i+LIF or serum+LIF.  
D) The growth rate of both WT and Ino80 KO cells.  
E) Quantitative qRT-PCR analysis of gene expression in wild type and Ino80 KO ESCs maintained in  
serum+2i+LIF.  
F) q RT-PCR analysis of gene expression in wild type and Ino80 KO ESCs maintained in serum+LIF. For 
all experiments N=3 biological replicates; * = t-test p-value ≤0.05).  
        A, B and C are done by Dr. Zhijun Qui. E and F are done by Veronica Peterkin. 
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3.3. Ino80 KO ESCs Fail to Differentiate Using In Vitro Differentiation Models. 
 We utilized in vitro differentiation models to further characterize the role of Ino80 
in mESCs differentiation. First, we created teratomas from both WT and KO mESCs 
maintained in ground state pluripotency medium by inoculating these cells into the 
opposing flanks of NOD/SCID mice. Once the control teratomas reached approximately 
1cm in diameter we harvested tumors and conducted routine histological analysis on 
tumor tissues. WT tumors differentiated into tissues from the three germ layers, which 
include blood islands, keratin pearls, and neural rosettes from the ectoderm lineage, 
both striated and smooth muscle from mesoderm and ciliated endoderm from the 
endoderm lineage (Figure 3.3 A & B a’,b’,c’,d’,e’ and f’). However, Ino80 KO teratomas 
displayed undifferentiated mesenchyme surrounded by a single layer of epithelial cells 
(Figure 3.3 A & B g’, h’).  
Secondly, we applied the embryoid bodies assay by suspension of WT and 
Ino80 KO mESCs maintained in ground state pluripotency medium into medium 
deprived of 2i and LIF. We harvested mESCs aggregates at three-day interval over nine 
days and analyzed these tissues histologically. WT embryoid bodies formed an 
organized mesenchyme filled with small cavities and surrounded by a defined layer of 
endoderm, while KO embryoid bodies formed disorganized mesenchyme with 
discontinuous endoderm (Coucouvanis et al.,1999) (Figure 3.3 C). We then quantified 
the levels of pluripotency and differentiation markers in both WT and Ino80 KO 
embryoid bodies. In contrast to pluripotency markers that exhibited approximately equal 
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levels in both WT and Ino80 KO embryoid bodies, differentiation markers showed a 
significant difference between WT and Ino80 KO embryoid bodies. The stem cell marker 
Bmp4 was upregulated, and subsequently its downstream endoderm markers Gata6 
and Gata4 (Cai et al., 2008 and Nemer et al., 2003). However, the levels of the 
ectoderm marker Fgf5 (Herbet et al., 1990), the endoderm marker Hnf4a (Duncan et al., 
1994) and mesoderm markers Fgf8 (Crossley et al., 1995) and T (Wilkinson et al., 
1990) (Figure 3.3 D) were reduced suggesting that pluripotency genes are Ino80-
independent while differentiation markers are Ino80-dependent. To identify the 
expression domain of Ino80, we used RNA in situ hybridization to determine where and 
when Ino80 is expressed starting with E5.5 embryo to the E7.5 embryo relying on sense 
and anti-sense probes. Results showed that Ino80 was widely expressed in E5.5 and  
E6.5 embryos mostly in the EmE and ExE with less staining in the VE (Figure 3.4 A,B, 
C). 
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Figure 3.3:  Ino80 is Essential for Embryonic Stem Cell Differentiation. 
A) Low-magnification analysis of differentiation potential of teratoma derived from wild type and Ino80 KO 
ESC (Scale bar = 500 µm). 
B) High magnification analysis of teratomas derived from both wild type and Ino80 KO ESCs (Scale bar = 
75 µm). 
C) H&E analysis of 9-day embryoid bodies derived from of wild type and Ino80 KO 606 ESCs (Scale bar = 
200 µm). 
 D) Gene expression analysis of differentiation markers in embryoid bodies derived from wild type or   
Ino80 KO ESCs over 9 days. For all experiments, N=3 biological replicates; * = t-test p-value ≤0.05. 
This figure is done by Dr. Zhijun Qui. 
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3.4 Ino80 KO Embryos Fail to Gastrulate. 
To further characterize Ino80 KO embryos, we applied the whole amount ISH to 
determine the expression of known developmental markers at the pre-gastrulation and 
gastrulation stages. We started with E6.5 embryos, the latest stage that failed develop, 
yet retained structural integrity. E6.5 is the time of gastrulation where the formation of 
the three germ layers (ectoderm, mesoderm and endoderm) occurs. Therefore, we 
stained embryos with probes for the mesoderm marker Brachyury (T) that is first 
detected in the pre-mesoderm cells and plays a role in the formation and organization of 
mesoderm at the onset of gastrulation (Wilkinson et al., 1990). In contrast to WT 
embryos, Ino80 KO embryos lack T expression, and presumably mesoderm 
differentiation is defective (Figure 3.4 D). Prior to gastrulation a subset of VE cells at the 
tip of the distal portion of the embryo migrate to the future anterior part to form the AVE 
that is identified by Hex1, Lefty1 and Cer1 expression. Formation of the AVE is 
essential for gastrulation. An analysis of these markers demonstrated that Ino80 KO 
embryos did not express the AVE markers Cer1, or Hex1, suggesting a failure to form 
the AVE. The ExE marker, Bmp4 is a member of the TGFβ family members and it is 
known to inhibit the formation of AVE (Winnier et al., 1995). Ino80 KO embryos 
exhibited very low expression of Bmp4 in the ExE (Figure 3.4 D). Collectively, these 
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results support the hypothesis that Ino80 KO embryos fail to gastrulate, do not specify 
the AVE and have abnormal Bmp4 expression in the ExE. 
Initiation of the P-D axis occurs at E5.5 when a subset of PrE cells differentiate at  
the distal part of the embryo to form the DVE. These cells are the precusors to the 
AVE. Because INO80 KO embryos lacked the AVE, we hypothesized that the DVE 
could be defective. Therefore, we measured the levels of Cer1, Hex1 and Bmp4 at E5.5 
embryos using whole mount ISH. Results revealed that the DVE markers, Cer1 and 
Hex1, were completely absent and the Bmp4 expression domain is mislocalized to the 
EmE. To further verify the localization of Bmp4 expression we performed a double 
staining of Bmp4 and Otx2. Otx2 is a known EmE marker at E5.5 embryos (Daisuke et 
al., 2004). As expected, we found an overlap between the two markers in the EmE 
(Figure 3.4 E) suggesting that Bmp4 expression is lower in the EmE in Ino80 KO 
embryos. Because, Bmp4 is a known regulator of the DVE these results suggest that 
In80 KO embryos fail to develop because of aberrant Bmp4 expression, a known 
negative regulator of the DVE. However, the defects in DVE specification could also 
result due to a general defect in VE. To test this possibility, we measured the levels of 
Hnf4a. Hnf4a belongs to the steroid hormone receptor family and it is expressed in VE 
endoderm at E5.5 and in the proximal VE at E6.5-E7.5 (Duncan et al., 1994). We 
observed reduced levels of Hnf4a in Ino80 KO embryos suggesting that Ino80 KO 
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embryos fail to specify the DVE due to mis-regulation of the inhibitory molecule Bmp4 
and possibly a defective VE (Figure 3.4 D). 
 PrE is the origin of several extra-embryonic tissues including that VE, EmVE, 
ExE and DVE (Stephenson et al., 2012). At E4.5, a subset of PrE cells differentiates into 
DVE cells that are retained at the distal part of the embryo. Consequently, the defects in 
DVE formation could be due to defect in PrE differentiation. To test this hypothesis, we 
stained E4.5 embryos with DVE markers Lefty1 and Hex1 and observed similar levels of 
these markers in both WT and Ino80 KO embryos suggesting normal differentiation of 
PrE cells. Also, the levels of the EPI specification marker Nanog in both WT and Ino80 
KO embryos was normal suggesting that its development in not INO80 dependent 
(Figure 3.4 D). The decreased embryo size at E6.5 is not likely due to cell death because 
TUNEL staining at this stage did not observe a significant difference between WT and 
Ino80 KO embryos (Figure 4 F). Based on the above results, Ino80 KO embryos fail to 
establish the P-D axis since they lack the ability to specify the DVE at E5.5. This could 
be due to abnormal expression of Bmp4 in the EmE, a known negative regulator of DVE 
differentiation or defects in VE differentiation. 
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Figure 3.4: Ino80 is Widely Expressed in Embryonic Tissues and is Essential for Establishing the 
Proximal-Distal Axis of the Post-Implantation Embryo.  
A) Whole mount RNA in situ hybridization using either sense or antisense Ino80 riboprobes in embryos at 
E5.5, E6.5 and E7.5 embryos. 
B) High magnification of Ino80 ISH exhibits reduced antisense Ino80 riboprobe staining in the visceral 
endoderm (VE) in E6.0-day embryos. 
C)Frozen sections of sagittal and cross-sections through the ExE and EPI stained with antisense Ino80 
riboprobe.  
D) Whole mount RNA in situ hybridization of E6.5, E5.5, and E4.5 embryos were performed with 
antisense riboprobes for markers of tissue differentiation. All ISH are done by Dr. Zhijun Qui except 
Hnf4a ISH. 
E) Whole mount ISH of E5.5 embryos were performed with antisense probes to the ExE marker Bmp4 
(purple color) and the EmE marker Otx2 (magenta color). 
F&G) Whole mount analysis and quantification of TUNEL positive cells in wild type and Ino80 KO E6.5 
embryos. N=3 biological replicates. 
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3.5. Ino80 Regulates Bmp4 Expression During Embryonic Stem Cell 
Differentiation In Vitro. 
Results from (Figure 3.3 D) showed upregulation of Bmp4 in Ino80 KO embryoid 
bodies. In addition, ISH experiments showed undetectable expression of Bmp4 in the 
EXE, and its upregulation in the EmE, suggesting a possible direct role of Ino80 in the 
regulation of Bmp4 expression. To identify how INO80 regulates Bmp4 expression, first 
we induced mESCs differentiation in vitro by LIF and 2i withdrawal from the media. LIF 
withdrawal from media is known to promote cell differentiation into mesoderm and 
endoderm lineages (Sharova et al., 2007 and Ying et al., 2003). We collected cells at 
three-day time interval over nine days. Then we quantified the RNA levels of Bmp4 and 
other differentiation markers. Results from monolayer differentiated cells were 
consistent with embryoid bodies experiments where Ino80 KO mESCs exhibited 
increased levels of Bmp4 expression, reduced levels of DVE markers Cer1, Hex1 and 
Lefty1 and approximately equal levels of the endoderm markers Gata4 and Gata6 
(Figure 3.5 A). In mESCs an upstream enhancer mediates transcription of Bmp4 
through interaction with Med23 and ETS1 (Wanqu et al., 2015).  
We applied ChIP analysis using monolayer differentiated mESCs cells to identify 
which Bmp4 regulatory element is occupied by INO80. As shown in Figure 3.5 B&C, 
Ino80 is preferentially localized to the promoter region of Bmp4. Next, we used FAIRE 
to detect the chromatin status at Bmp4 promoter under the same condition. Results 
showed an open chromatin structure at ~ 1.5 Kb upstream of Bmp4 promoter (Figure 
3.6 A, B). SP1 is a transcription factor that is known to activate Bmp4 expression (Ebara 
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et al., 1997), so we applied ChIP experiment to monitor its localization at the Bmp4 
promoter, and we observed that SP1 occupies the promoter region of Bmp4 with 
enrichment of the active histone marker H3K4me3 (Figure 3.6 C, D). Based on the 
above data, we provide a model where the chromatin remodeling factor INO80 is 
required for DVE specification in pre-gastrula mouse embryo by negative regulation of 
Bmp4 in the EmE and by positive regulation of Bmp4 in the ExE (Figure 3.7) and also 
by its effect on VE differentiation through Hnf4a down-regulation. 
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Figure 3.5: Ino80 Regulates Bmp4 Expression by Occupying its Promoter.  
A) qRT-PCR quantification of Bmp4, Hex, Lefty1, Cer1, Gata6, and Gata4 during ESC differentiation in 
the absence of 2i+LIF in monolayer.   
B) Cartoon showing the cis-regulatory elements of Bmp4 gene, location of upstream enhancers, and 
downstream gene Gm15217 to illustrate position of PCR amplicons used in ChIP experiments. Amplicons 
are shown as black bars labeled 1-6ChIP of both wild type and Ino80 KO ESC after differentiation as a 
monolayer for 6 days in serum containing media in the absence of 2i+LIF.  
For all of the above experiments N=3 biological replicates; * = t-test, p-value ≤0.05.  
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Figure 3.6: The Bmp4 Promoter is More Accessible to Positive Regulatory Factors upon Ino80 
Deletion. 
A) Cartoon showing ~ 1.5Kb of the Bmp4 promoter and the location of PCR amplicons used in FAIRE 
experiments.  
B) FAIRE was performed with wild type and Ino80 KO ESC after differentiations for 6 days in culture 
media containing serum and lack both 2i+LIF.  
C) Increased occupancy of active chromatin mark H3K4me3 at Bmp4 promoter in Ino80 KO ESC as 
compared to WT. ChIP was performed using wild-type and Ino80 KO ESC after differentiation as a 
monolayer for 6 days in serum containing media lacking 2i+LIF.  
D) Increased occupancy of the positive transcription factor SP1 at Bmp4 promoter in Ino80 KO ESC as 
compared to WT ESCs. ChIP was performed with wild type and Ino80 KO ESC after differentiation in 
serum containing media lacking 2i+LIF as a monolayer for 6 days. 
For all of the above experiments N=3 biological replicates; * = t-test, p-value ≤0.05.  
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Figure 3.7: Model of Ino80 KO Effect on Bmp4 Gene Expression and its Consequences on the   
Establishment of the Proximal-Distal Axis in Early Mouse Embryo. 
We propose a model where Ino80 KO embryos upregulate Bmp4 expression in the EmE, which in turn 
repress the expression of the DVE markers Cer1, Hex, and Lefty1. Consequently, Ino80 KO embryos lack 
the DVE in part due to mis-localized Bmp4 expression and fail to gastrulate. 
 
 
 
 
 
 
 
 
 
A Proposed Model INO80 Role in DVE Formation during Early Mouse Development. 
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CHAPTER FOUR 
Discussion and Future Directions 
 
4.1 Discussion  
4.1.1 Early Embryonic Lethality Due to Disruption of the ATP-Dependent 
Chromatin Remodeler INO80 
Mammalian development is a complex process in which one cell zygote give rise 
to an organism. An organism is composed of multiple cell types that develop into 
specific tissues and organs. Although all these cells share the same genetic DNA 
sequence, the chromatin state (DNA packaging) is distinguished in each cell type to 
establish and maintain different cell identities. The chromatin state is modified by many 
mechanisms including histone post-translation modifications (for example, histone 
acetylation, and methylation), histone variants, and DNA modifications like cytosine 
methylation and/or ATP-dependent chromatin remodeling complexes (Ho et al., 2010 
and Chen et al., 2014). 
Genetic studies utilizing mouse models showed essential roles of chromatin 
remodelers in development. Chromatin remodelers are important for both pre- and post- 
implantation phenotypes suggesting that they regulate specific developmental 
pathways. NURD is required for maintaining the balance between self-renewal and 
differentiation. Pre-implantation lethality occurs upon deletion of the methyl CpG-binding 
domain protein 3 gene (MBD3) that encodes the core component of NURD (Kaji et al., 
2007). MOF/TiP60 null embryos fail to implant and survived blastocysts are defective in 
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morphology and growth suggesting an essential role for the complex in cell survival, 
pluripotency and self-renewal (Thomas et al., 2008). Mouse embryos null for the 
SWI/SNF ATPase subunit Brg1 die before implantation suggesting a potential role of 
Brg1 in self-renewal and pluripotency in mESCs (Bultman et al., 2006). Other chromatin 
remodeling factors such as NURF and CHD7 exhibit post-implantation lethality upon 
deletion. NURF (BPTF) KO embryos are defective in gastrulation and differentiation of 
mesoderm and endoderm (Landry et al., 2008). CHD7 null embryos showed multiple 
defective tissues and perinatal lethality (Hurd et al., 2007). In the present study, we 
show that Ino80 KO embryos fail to gastrulate and exhibit post-implantation lethality. 
4.1.2 The Differential Effect of Ino80 KO in MEFs and mESCs 
 DNA replication is an essential component of cell proliferation. Chromatin 
remodeling at replication origins is an essential step in DNA replication especially at 
stalled forks.  Ino80 is required for DNA replication where it disrupts nucleosomes in 
front of replication fork to facilitate polymerase movement and DNA unwinding at 
replication origin (Karina et al., 2012). It is also required to re-assemble disrupted 
nucleosomes behind the fork.  Lee et al. showed that Ino80 is stabilized by BAP1 
through de-ubiquitination and BAP1 recruits Ino80 to replication fork by its interaction 
with ubiquitinated H2A. These functions might explain in part the early embryonic 
lethality in Ino80 KO mice, non-viable Ino80 KO MEFs, and slow growth rate of Ino80 
KO ESCs (Min et al., 2013 and Lee et al., 2014). 
Our results showed that Ino80 KO MEFs have significantly higher beta- 
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galactosidase than WT MEFs. This is consistent with a recent study, which showed that 
Ino80 is required for MEF proliferation, and its deletion delayed S-phase progression 
and decreased BrdU (bromodeoxyuridine) incorporation (Hur et al., 2010, Min et al., 
2013 and Lee et al., 2014). Although the same study reported that Ino80 KO ESCs were 
not viable. In our hands, Ino80 KO ESCs were viable when cultured in medium supplied 
with 2i plus LIF to maintain ground state pluripotency. ESCs that grow in 2i medium 
exhibit global hypomethylation of DNA that is similar to hypomethylated ICM at E3.5 
(Leitch et al., 2013). DNA hypomethylation alters chromatin structure to promote gene 
activation (Feinberg et al., 1983). INO80 is involved in regulation of gene expression 
(Ebbert et al., 1999), occupies the promoters of pluripotency genes in ESCs, and 
regulates their expression (Li et al., 2014). In addition, INO80 replaces the histone 
variant H2A.Z with H2A. H2A.Z occupies promoters of poorly transcribed genes (Zhang 
et al., 2005), possibly to facilitate their expression (Manolis et al., 2011). It is plausible, 
and I hypothesize that DNA hypomethylation of ESCs in ground state activates gene 
expression, compensating for INO80 functions in maintaining gene expression. These 
same compensatory effects would not be relevant in MEFs, which have 
hypermethylated promoters, and require INO80 to maintain gene expression. 
 In contrast to MEFs, mESCs exhibit unique characteristics to stay pluripotent. 
mESCs are characterized by the ability to self-renew in vitro while maintaining 
pluripotency, i. e. the capacity to differentiate into a broad number of cell types that 
originate from the three primary germ layers endoderm, mesoderm and ectoderm  
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(Evans and Kaufman, 1981; Martin, 1981). The potential to self-renew is marked by two 
main characteristics: highly rapid proliferation and high telomerase activity. The high 
proliferation rate of mESCs necessitate unique cell cycle, which have extremely short 
G1 phase that is devoid of regulation at the G1–S transition due to the absence of cyclin 
D and the presence of hyperphosphorylated retinoblastoma (RB1) protein (Savatier et 
al., 1996; Burdon et al., 2002). Both c-Myc and Klf4 are essential factors for mESCs 
pluripotency (Kazutoshi et al., 2006). Klf4, which is known to repress p53 directly 
(Rowland et al., 2005), while c-Myc, suppresses the expression of p21CIP1 (Seoane et 
al., 2002). Both p53 and p21CIP1 are involved in cell cycle regulation and their 
repression facilitate cell cycle progression in mESCs. mESCs express high levels of 
TERT and exhibit high telomerase activity.  TERT is a ribonucleoprotein enzyme, which 
synthesis telomeres to maintain telomere homeostasis in mESCs and prevents 
telomeres fusion to keep cells genetically stable (Wong et al., 2010). This difference in 
cell cycle regulation and proliferation suggest that mESCs could compensate for Ino80 
KO while MEFs could not. 
4.1.3 Ino80 KO Effect on the Pluripotency of mESCs. 
 In our model, Ino80 is required for metastable but not ground state pluripotency 
in Ino80 KO mESCs as similarly observed for Mbd3 KO mESCs (Kaji et al., 2007). 
Ino80 KO mESCs exhibited WT pluripotent phenotype when those cells are maintained 
in medium that promote ground state pluripotency (2i+LIF). However, when those cells 
maintained in medium that induce metastable pluripotency (LIF only) they differentiate 
and lose their pluripotent phenotype. 2i can closely mimic the in vivo environment for  
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ICM pluripotency (Marks et al. 2012) and mask defective pluripotency due to Ino80 KO. 
Our results contradict the finding that Ino80 is required for mESCs pluripotency and pre-
implantation (Wang et al., 2014). This could be due to difference in Ino80 KO methods, 
since referenced study used siRNA to KD Ino80, which could affect both maternal and 
embryonic tissues (Li et al., 2014). In addition, the referenced study maintained the cells 
in culture medium that promotes metastable pluripotency, culture conditions that we 
have shown requires INO80. Another possibility, at the metastable pluripotency state, 
nucleosomes are highly modified by the activation marker H3K4me3 (Marks et al., 
2012), which could recruit activating histone readers to promote gene expression and 
compensate for the loss of INO80. Under these conditions factors like Sox2, Nanog, 
Oct4, which require INO80 in the metastable state, would sufficiently transcribed 
maintaining pluripotency. 
4.1.4 The Reduced Size of Epiblast in Ino80 KO Embryos 
 The Ino80 KO embryos have reduced size at E6.5, which could be due to 
reduced proliferation or increased apoptosis rates. Ino80 KO did not affect the levels of 
apoptosis, as the rates of cell death were essentially similar in both WT and Ino80 KO 
embryos. It has been shown that E5.5 embryo undergo dramatic increase in 
proliferation to attain a certain number of cells to start the gastrulation at E6.5 (Snow et 
al., 1977). Consequently, the reduced embryo size could be due to the reduced 
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proliferation rate of Ino80 KO mESCs. This possibility could be further investigated by 
the determination of the epiblast proliferation rate at E6.5 through BrdU labeling of  
embryos and/or the measure of cell proliferation using immuno-histochemistry of 
phosphorylated histone H3 levels in the conceptus by at E6.5 and E7.5 (Landry et al., 
2008). 
4.1.5. Ino80 KO Effect on the Proximal-Distal Axis Establishment 
 The A-P axis establishment is induced by AVE formation at the anterior part of 
pre-gastrula embryo, which in turn promotes gastrulation (Beddington and Robertson, 
1999). Both TGF-β signaling molecules, Nodal and Bmps, are involved in the regulation 
of DVE formation at E5.5 (Brennan et al., 2001 and Soares et al., 2005). The 
antagonism between these two molecules at the distal part of the embryo is the 
molecular basis of DVE formation. Nodal -/- embryos fail to specify embryonic VE which 
is required to develop the DVE (Mesnard et al., 2006). Furthermore, inhibition of Nodal 
signaling abolished DVE formation, and promoted aberrant Bmp4 expression at the 
DVE (Yamamoto et al., 2009). Although the levels of Nodal transcripts were similar in 
both WT and Ino80 KO embryos, Nodal could be unprocessed, and therefore not 
functional in Ino80 KO embryos, resulting in defective DVE formation for reasons 
discussed above (Mesnard et al., 2006). 
 In WT embryos, Bmp4 is expressed in the EXE at the pre-gastrula and gastrula 
stages. Limited expression of Bmp4 in the ExE is required for DVE establishment, 
because it is a negative regulator of the DVE (Rodriguez et al., 2005; Mesnard et al., 
2006)(Yamammoto et al., 2009). In addition, Bmp signaling is required for VE 
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differentiation at E5.5, and it cooperates with Nodal signaling to promote epiblast 
proliferation. In our model, Bmp4 expression is up regulated in the EmE thereby 
emitting an inhibitory signal for DVE formation. Defective DVE formation could be also 
result from impaired VE as suggested by the down-regulation Hnf4a, possibly also a 
result from aberrant Bmp4 expression (Figure 4 D). 
 VE is the main expression domain of Hnf4 during gastrulation and its disruption 
results in defective gastrulation (William et al., 1994). VE is an outer layer of epithelial 
cells around the embryo. The tight junctions between these epithelial cells are essential 
for nutrition and small molecule delivery to the embryo. It is also the main site for 
production of survival signals (Jollie et al., 1990). It would be interesting to examine the 
endocytic activity of VE in Ino80 KO embryos, which could contribute to the lethality 
phenotype. Signals from ExE are required for VE patterning and DVE formation 
(Richardson et al., 2006). To determine if VE defects in Ino80 KO embryos are the 
result of an overall defective ExE, we can monitor the expression pattern of additional 
ExE markers including, Fgfr2, Plet1 and Talia using in situ hybridization (Stephen et al., 
2007). FGF signaling is involved in the development of extraembryonic tissues and 
FGFR2 is required for ICM differentiation and specific functions of the trophectoderm 
(Arman et al., 1998). The initial establishment of the cardiovascular network occur 
during gastrulation at E6.5 (Nowotschin et al., 2010). This process is largely dependent 
on activation of the vascular endothelial growth factor (VEGF) signaling pathway. The 
vascular endothelial growth factor receptor 2 (VEGFR2/Flk1) is critical for the  
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development of the primitive capillary plexus during embryogenesis (Klagsbrun and 
Soker, 1993). Flk1 is a receptor tyrosine kinase that is expressed in the extra-embryonic 
ectoderm. Flk-1 KO embryos die at E8.5-E9.5 due to defect in the development of 
hematopoietic and endothelial cells (Shalaby et al., 1995). We can also quantify the 
expression of these angiogenic markers VEGFR2 and Flk1 at E6.5 to detect any 
defective angiogenesis phenotypes associated with Ino80 KO. While defects in 
angiogenesis are unlikely to contribute the lethality of Ino80 KO early embryos, it could 
reveal important functions for INO80 in these processes, which would have relevance to 
our understanding of INO80 in the adult. 
4.1.6. INO80 Regulation of the Bmp4 Promoter  
The roles for INO80 as a chromatin-remodeling factor that regulates gene 
expression is well established. Towards this end, transcription factors can recruit INO80 
to target genes where it can modulate chromatin and activate or repress expression. 
Our results demonstrated a differential regulation of Bmp4 by INO80 at the 
transcriptional level in the ExE and EmE where Bmp4 expression is inhibited in ExE and 
upregulated in EmE. More specifically in the EmE we predict that INO80 is modulating 
the chromatin structure at Bmp4 to prevent access of regulatory factors such as SP1. 
How INO80 is recruited to the Bmp4 promoter is unknown, but could be through 
interactions with unknown transcription factors. Also, enhanced H3K4me3 at the Bmp4 
promoter in Ino80 KO ESCs could recruit other unknown regulatory factors that promote 
Bmp4 expression beside SP1. For example, the mediator complex is a multi-protein  
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complex that mediates a connection between transcription factors and the mRNA 
polymerase II apparatus to regulate gene activity (Kagey et al., 2010). In ESCs, the 
mediator subunit med23 recruit ETS1 (member of the ETS family transcription factors) 
to the Bmp4 promoter and enhancer to facilitate their communication and enhance 
Bmp4 expression (Wanqu et al., 2015). In addition, USF (upstream stimulatory factor) 
binds the Bmp4 promoter and activate its expression (Ebara et al., 1997). The 
recruitment of either of these factors could be repressed by INO80 in the EmE. To test 
these hypotheses ChIP analysis of these factors at the Bmp4 promoter in Ino80 KO 
ESC would be performed which could reveal additional regulatory factors of Bmp4. 
4.2 Future Directions 
The role of mouse INO80 in DNA repair, DNA replication, the cell cycle regulation 
and telomere replication demonstrates it’s requirement for the maintenance of genomic 
stability (Wu et al., 2007 and Hur et al., 2010). Mouse Ino80 deletion reduced the 
tumorigenic potential of oncogenic transformed cells by reduction in cell proliferation 
and impairment of their ability to form soft agar colonies (Min et al., 2013). In addition, 
mouse Ino80 haploinsufficiency in a p53 KO background induced a shifted in the tumor 
spectrum form lymphoma to sarcoma suggesting a role for Ino80 in tumor suppression 
and determination of the cells fate that will initiate cancer (Min et al., 2013). A recent 
study showed that INO80 promotes cervical cancer proliferation through activation of 
Nanog, expression and its inhibition reduced cell proliferation in vitro and in vivo (Hu et 
al., 2016). The INO80 complex is an enzyme with multiple binding sites for its  
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substrates that could be targeted by small molecules to inhibit its activity. It has been 
shown that HSA/PTH and Snf2 ATPase domains of human Ino80 are essential for its 
remodeling activity (Lu et al., 2011). Targeting these subunits will inhibit the complex 
remodeling and enzynmatic acitivities. However, the consequences for INO80 depletion 
could be very detrimental to normal cells. The INO80 complex is crucial for essential cell 
processes such as DNA replication, cell cycle regulation, chromosomes segregation 
and telomere maintenance (Ashby et al., 2009). 
Beyond cancer, the defective differentiation of Ino80 KO ESCs suggests a 
possible role of Ino80 in tissue regeneration. This could be tested by tissue specific KO 
of Ino80 in the liver for example and chemical induction of liver injury followed by 
assessment of the recovery rate in both WT and KO mice (Dimitrios et al., 2013). 
 
 
 
 
 
 
 
 
 
  
  
    
  
 
69 
 
PART II. Role of the Nucleosome Remodeling Complex NURF in Anti- 
Tumor Immunity 
Chapter 5. Background and Literature Review 
 
5.1 The Immune System    
The immune system is classically divided into innate and adaptive immune 
systems. The innate response is fast and it includes a broadly distributed variety of 
myeloid and lymphoid cells (e.g. monocytes, neutrophils, macrophages, dendritic cells 
and natural killer (NK) cells). However, the adaptive immune response is slow since it 
requires proliferation and differentiation of effector cells, which include T and B cells. T 
and B cells express an unlimited repertoire of antigen receptors that are produced by 
gene rearrangement (Vivier et al., 2011). NK cells are a type of lymphocytes that plays 
an important role in innate immune processes, including early defense against different 
pathogens and tumor transformation through a limited repertoire of germline-encoded 
receptors. They comprise up to 15% of peripheral blood lymphocytes and are found in 
peripheral tissues such as liver, spleen, peritoneal cavity and placenta (Trinchieri et al., 
1989).  
5.2 NK Cell Development 
NK cells was first discovered by Rolf Kiessling, 40 years ago, when he 
characterized a subset of large granular lymphoid cells that directly lyse tumor cells in 
vitro without prior sensitization a phenomenon known as ‘natural cytotoxicity (Kiessling  
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et al., 1975). The evolutionary origin of NK cells is not completely understood. NK cells 
complete functional and phenotypic maturation in the bone marrow (BM) and their 
functional differentiation requires their direct interaction with BM stromal cells in vitro 
and in vivo (Caraux et al., 2006).  The development of NK cells can be divided into 
several stages (Figure 5.1). The earliest stages involve the commitment of 
hematopoietic stem cell (HSC) in BM into a common lymphoid progenitor (CLP) that can 
give rise to NK, T and B cells. The CLP is characterized by expression of IL-7R 
(CD127), c-kit (CD117), Sca-1, and Flt-3 (CD135) (Kondo et al., 1997). The CLP 
differentiates into bi-potential T/NK progenitor cell reflecting the resemblance between 
NK and T cells (Rodewald et al., 1992 and Schmitt et al., 2006). In order  for the T/NK 
cell progenitor to commit to NK progenitor, they acquire the IL-2/15Rα subunit (CD122). 
Accordingly, mice deficient in IL-15 receptor or its signaling components is defective in 
NK cell development (Suzuki et al., 1997, Ogasawara et al., 1998, and Kennedy et al., 
2000). NK progenitors develop into immature NK (iNK) cells that lose IL-7R expression 
and acquire expression of NK1.1 (Rosmaraki et al., 2001). Immature NK cells develop 
into functionally mature NK cells by expression of CD11b, CD43, Ly49 receptors, and 
CD49b (DX5). Once mature these NK cells have the ability to lyse target cells and 
produce IFN-γ (Kim et al., 2002). 
 
 
 
 
 
  
  
    
  
 
71 
 
 
 
 
 
 
Figure 5.1: Cartoon Illustrating the Stages of NK Cell Development. 
NK cells are derived from the CLP, which differentiates into NKP/ILCP population distinguished from the 
NKP by lack of CD122 expression. The NKP, begin to express NK cell markers NK1.1 and NKp46, and 
as they further mature they acquire expression of DX5 (CD49b) and CD11b while losing expression of 
CD27. As NK cells mature they also gain functional competence, expressing lytic molecules and 
cytokines such as IFNγ. Color-coded cell surface proteins indicate the stage where proteins are first 
expressed. Loss of a specific cell surface marker is indicated by parentheses (Geiger et al., 2016). 
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5.3 Regulation of NK Cytotoxicity  
NK cell education/licensing is the process by which they become functionally 
competent (Fernandez et al., 2005). There are many models for NK cells’ education: 
(1). The arming hypothesis proposes that the self-MHC class I specific receptors 
generate the signals necessary to confer the licensed phenotype, whereas signaling 
from inhibitory receptors mediates functional maturation in an active way. (2) The 
disarming hypothesis suggests the presence of a self-specific activation receptor. If 
unperturbed, the activation of this receptor results in chronic stimulation and an anergic-
like, hypo-functional state. The self-MHC-I specific receptor then modulates the action 
of the activation receptor and leads to a licensed NK cell (Elliot et al., 2011). (3) The 
rheostat model suggests that NK cells’ education depend on the strength of the 
inhibitory signal that is received which can be tuned up or down in a quantitative manner 
(Petter et al., 2010).  
Once “educated”, NK cells are able to kill pathogen infected or transformed cells 
without prior sensitization. NK killing occurs though a variety of mechanisms, including 
perforin/granzyme granule-mediated exocytosis, and/or signaling through the TNF 
death receptor family members (Smyth et al., 2005). The granule exocytosis pathway 
depends on NK cytotoxic and cytoplasmic granules, which resemble the secretory 
lysosomes. These granules contain the mediators of a diverse range of cell-death 
pathways that have evolved to rapidly kill target cells. The major components of these  
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granules are perforin, a membrane-disrupting protein, and granzymes. Both are related 
to a family of serine proteases with various substrate specificities. Perforin gene 
disruption in mice indicated that perforin is essential for NK cell cytotoxicity and it has an 
indispensable role in granzyme-mediated apoptosis (Kagi et al., 1994). Granzymes are 
highly redundant, there are eleven granzymes, ten of these (granzymes A–K, M and N) 
are expressed in mice, and five in humans (granzymes A, B, H, K and M) (Smyth and 
Trapani, 1995 and Trapani et al., 2000). Granzymes trigger cell apoptosis either directly 
or via activation of caspases (Heusel et al., 1994). 
 The death receptor pathways involve the interaction between a death receptor on 
target cells and their cognate ligands on NK cells, which results in caspase-dependent 
apoptosis. The death TNF (Tumor necrosis factor) ligands on NK cells includes TRAIL, 
FasL and other mediators. TRAIL (TNF-related apoptosis-inducing ligand), is a type II 
transmembrane protein that belong to the TNF superfamily. Both mouse and human NK 
cells express high levels of TRAIL in response to IL-2, IL-15 and IFN treatment 
indicating a broad role of TRAIL in innate immune response. The cytotoxic and anti-
metastatic activity of NK cells toward TRAIL sensitive tumor cells is in part dependent 
on TRAIL (Takeda et al., 2001a) interaction with TRAIL-R1 (DR4) and TRAIL-R2 (DR5) 
resulting in an apoptotic signal (Degli-Esposti, 1999). In addition, FasL expression by 
NK cells suppress tumor growth in vivo (Bradley et al., 1998). In response to IFNγ 
secretion, NK cells directly induce Fas expression on tumor cells to kill them in a Fas-
dependent manner (Screpanti et al., 2001). In addition, TNF deficient mice were  
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defective in rejection of NK sensitive tumor cells indicating that the death receptor 
pathway is an important mechanism for NK cells clearance of tumor (Smyth et al., 
1998).   
5.4 Regulation of NK Cells Activity 
The regulation of NK cells is not dictated by one dominant receptor with high and 
specific affinity towards one particular antigen. Instead, each NK cell has broad 
specificity, which is mediated by the expression of multiple activating and inhibitory 
receptors. For many years, NK cells were considered as non-specific effectors until 
Klas-Karre first postulated his ‘missing self’ hypothesis in 1986 (Karre et al., 1986). 
According to this theory, NK cells can recognize and spare cells that express self-
markers the MHC class I molecules. Based on this hypothesis, the activity of NK cells is 
based on their ability to sense what is missing on a target, but present in a healthy cell. 
The ‘missing self-hypothesis’ predicted that NK cells must express inhibitory receptors 
that interact with the self MHC class I molecules and deliver an inhibitory signal upon 
interaction. However, NK-mediated killing is regulated by other non-MHC ligands. 
Indeed, certain MHC class I negative molecules are resistant to NK killing and others 
with MHC class I molecules are NK susceptible targets. Thus, NK cell activity is not only 
dependent on the absence of the inhibitory signal but also require the engagement of 
their activating receptors (Moretta et al., 1995, Markel et al., 2002). The following 
sections will describe the central components that participate in the delivery of both  
inhibitory and activating signals and determine the overall regulation of NK activity, as 
known today.  
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5.4.1 Inhibitory Receptors 
All of the well-defined NK inhibitory receptors contain one or more copies of the 
immune receptor tyrosine-based inhibitory motif (ITIM) in their cytoplasmic tail. Upon 
ligation of the receptor, the Tyr residues in the ITIM are phosphorylated (probably by 
Src family kinase) and recruit phosphatases via their SH2-domains. The recruitment of 
the phosphatases to a membrane proximal location dampen or prevents activating 
signals. Under normal circumstances, these inhibitory signals predominant those 
delivered by activating receptors (Lanier et al., 2005).  However, experimental evidence 
shows that the degree of inhibition is proportional to the level of inhibitory ligands 
expressed on the target cells. In addition, when multiple costimulatory receptors are 
spontaneously engaged, or when a sufficient activating signal is delivered (by the 
ligation of a potent lysis receptor), NK cells are capable of overcoming the inhibition and 
destroy the target in spite of the existence of high levels of inhibitory ligands (Moretta et 
al., 2002). 
 NK inhibitory receptors can recognize ‘classical’ and ‘non-classical’ MHC class I 
ligands. The two major families of MHC-specific inhibitory receptors identified in humans 
include; The Ig superfamily, which includes the killer and leukocyte immunoglobulin-like 
receptors, designated as KIR and LIR, respectively and the C-type lectin receptor 
superfamily in both human and mice (Raulet et al., 2001). The KIR proteins belong to 
the Ig-superfamily of proteins have 2 or 3 immunoglobulin (Ig)-like domains and either a  
short or a long cytoplasmic tail.  The KIR molecules with a long cytoplasmic tail signal 
via ITIMs to transduce a negative signal, whereas the KIRs with a short cytoplasmic tail 
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signal via ITAM mediated recruitment of DAP12 and thus inhibit the NK cell’s activity 
(Raulet et al., 2001).    
The KIR family in humans, the lectin-like Ly49 molecules in mice and 
CD94/NKG2A heterodimers in both species are the most relevant and best-studied 
inhibitory receptors.  The KIR loci in human and the Ly49 loci in mice are highly 
polymorphic both in terms of gene numbers (14 genes and 2 pseudogenes) and alleles 
present. Other inhibitory molecules include KLRG1 (Killer Cell Lectin-Like Receptor 
Subfamily G member 1), TIGIT (T cell immunoreceptor with Ig and ITIM domains), NKR-
P1A or LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2) (Aron 
et al., 2006). These molecules detect cadherin, CD155 and CD112 and/or a broad array 
of HLA-A, -B, -C and -G alleles and thus complement the capability to distinguish “self” 
from “altered self” or “missing self”. All mentioned receptors signal via ITIMs that 
subsequently recruit and activate the phosphatases SHP1 and SHP2, thus decreasing 
the absolute signal strength.  
 Importantly, NK cells in one given individual can vary in terms of which KIR 
alleles are expressed and the level of expression creating different populations of KIR 
positive NK cells. The fact that KIR alleles are expressed in a largely random manner, 
unlinked from the host’s HLA haplotypes, is troublesome as this potentially could cause 
NK cell mediated autoimmunity. Therefore, an education system exists in which 
developing NK cells acquire self-tolerance if they fail to bind to self-HLA. This state of  
hypo-responsiveness not only affects reactivity to self but also affects stimulation with 
MHC class I negative tumor cells, or plate-bound antibodies against various stimulatory 
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receptors. The same phenomena can be observed when mice or human individuals lack 
HLA class I molecules (Natalia et al., 2014).  
5.4.2 Co-stimulatory NK receptors 
Surprisingly, most the MHC class I-dependent inhibitory receptors have a 
stimulatory homolog counterpart. Under normal conditions, the affinity of stimulatory 
receptors to their MHC class I ligands is lower than their inhibitory counterparts are so, 
the inhibitory signal dominate the stimulating ones (Vales-Gomeset al., 1999). A 
possible explanation is that these receptors may be involved in a different context and 
recognize additional ligands. For example, both the CD94/NKG2C stimulatory and its 
inhibitory counterpart the CD94/NKG2A, recognizes HLA-E. However, NKG2C is 
activated by peptides derived from the heat shock protein Hsp60 bound to the HLA-E 
molecules under stress conditions (Michaelsson et al., 2002). 
5.4.3 NK Activating Receptors 
 The difference between NK co-stimulatory and activating receptors is their ligand 
specificity. While the stimulatory receptors recognize MHC class I ligands, the triggering 
receptors recognize non-MHC ligands. Moreover, the activating receptors are able to 
mediate direct killing of targets and therefore considered as lysis receptors. In resting 
NK cells, the cytolysis activity requires synergistic stimulation of more than one receptor 
(Bryceson et al., 2005). Progress in the understanding of NK cell biology revealed that 
NK cell activation is not only dependent on the absence of the inhibitory signal; it also  
requires efficient activating signals. This theory is based on the discovery of a set of NK 
activating receptors that are able to directly induce cytotoxicity and cytokine production  
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upon engagement.  The major NK activating receptors include the NKG2D, CD16 and 
the NCRs (natural cytotoxic receptors), which include NKp46, NKp44 and NKp30 
(Moretta et al., 2002). In addition, some NK receptors are thought to serve as 
‘costimulatory’ receptors that enhance signaling of active receptors but cannot mediate 
cytotoxicity on their own.  The following sections will discuss the major NK triggering 
receptors and their ligands.   
NKG2D is a type II transmembrane glycoprotein that is expressed on the surface 
of all human and mouse NK and a subset of T cells (Bauer et al., 1999 and Jamieson et 
al., 2002). The identified ligands for NKG2D include MICA, MICB and ULBP1-4 in 
human and H60, Rae1 in mice (Bauer et al., 1999, Castriconi et al., 2003 and 
Sutherland et al., 2002). These proteins are stress inducible cellular ligands that are 
structurally homologous to MHC class I proteins (Li et al., 2001). NKG2D is involved in 
anti-viral defense mechanisms. For example, CMV infection leads to upregulation of 
NKG2D ligands (Groch et al., 2001). In response to this challenge, CMV developed 
evasion mechanisms, which include the expression of UL16 protein (Cosman et al., 
2001). UL16 binds NKG2D ligands and prevents their transport to the surface of 
infected cell to reduce NK cytolysis activity (Wu et al., 2003 and Dunn et al., 2003).   
   In tumors, NKG2D ligands are upregulated due to genotoxic stress and stalled 
DNA replication and in vivo, expression of NKG2D ligands induce NK-mediated 
elimination of NK-resistant tumor cell lines (Cerwenka et al., 2000 and Diefenbash et al.,  
2001). Tumor cells avoid NK-mediated killing via NKG2D receptor, by shedding of 
NKG2D ligand from their surface. Indeed, high levels of soluble MIC proteins were  
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detected in sera of cancer patients (Grosh et al., 2002). In addition, tumors upregulate 
TGF-β (a known immunosuppressive factor) that might induce downregulation of 
NKG2D receptor on lymphocytes (Castriconi et al., 2003).  
The NCRs are highly conserved among species even at the level of their cellular 
ligands (Moretta et al., 2002). The only functional NCR homolog expressed in mice is 
the murine NKp46 (NCR1) (Biassoni et al., 1999). NCRs are preferentially expressed on 
NK cells and induce NK cytotoxicity upon cross-linking by specific monoclonal 
antibodies. A functional crosstalk between the three NCRs was suggested since upon 
ligation of a single NCR also induces signaling cascades of other NCRs (Augugliaro et 
al., 2003). Accumulating evidence suggested that NCRs have important roles in 
recognition and killing of tumor cells. NCRs blocking prohibited NK-mediated killing of 
many tumor cell lines and in vivo, downregulation of NCRs or their ligands in acute 
myeloid leukemia cells rendered them resistant to NK cytotoxicity (Biron et al., 2001 and 
Costello et al., 2002).   
 NKp46 is the first identified member of NCRs (Sivori et al., 1997). NKp46 is 
specifically expressed on NK cells, and a minor population of innate lymphoid cells 
(Gazit et al., 2004). NKp46 cross-linking induced calcium mobilization, cytotoxicity and 
cytokines release (Sivori et al., 1997). Upon engagement, NKp46 is associated with the 
adaptor molecules CD3ζ and FcуR, which have the activation ITAM motif (Pessino et 
al., 1998 and Falco et al., 1999). In humans, NKp46 is a 46KDa glycoprotein with two  
Ig-like extracellular domains and three potential glycosylation sites located at positions 
Thr125, Asp215 and Thr225 (Pessino et al., 1998). The membrane proximal domain of  
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NKp46 is sufficient for the binding of NKp46 to tumor cells. However, it has been  
suggested that the membrane-distal domain of the receptor is dispensable for its 
function (Arnon et al., 2004). Recently, it was reported NKp46 and NKp30 involve 
heparin sulfate in the recognition of tumor cells (Bloushtain et al., 2004). In addition, it 
has been shown that high cell surface heparanase (heparin sulfate degrading enzyme), 
or low heparin sulfate expression on tumor cells, rendered them less susceptible to NK-
mediated killing. Similarly, the absence of heparin sulfate expression reduced NK 
mediated lysis (Bloushtain et al., 2004). 
  NKp44 encodes a 44 KDa surface glycoprotein. Antibody blocking of NKp44 
partially inhibited cytotoxicity against NK susceptible targets (Vitale et al., 1998). 
However, simultaneous blocking of both NKp44 and NKp46 led to a significant inhibition 
of NK cells activity (Vitale et al., 1998), suggesting a functional cross talk among these 
receptors (Augugliaro et al., 2003). In contrast to other NCRs, NKp44 is not expressed 
on resting NK cells, but it is upregulated in response to IL-2 activation in vitro (Vitale et 
al., 1998). In vitro upregulation of NKp44 by IL-2 may explain the enhanced cytotoxicity 
of IL-2 activated NK cells towards non-MHC restricted targets. Very little information is 
known about the cellular ligands of NKp44. The only identified ligand for NKp44 so far is 
the hemagglutinin (Arnon et al., 2001).  
 NKp30 was shown to synergize with NKp46 and NKp44 to enhance cytotoxicity, 
however, it also induces killing of targets that are NKp46/44-independent (Pessino et  
al., 1998 and Moretta et al., 2000). NKp30 is expressed on resting as well as activated 
NK cells (Moretta et al., 2000). NK cells incubation with TGF-β1 reduces NKp30  
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cytolysis activity suggesting a possible mechanism by which tumor cells that produce  
TGF-β evade NK response (Castriconi et al., 2003). NKp30 was also suggested to 
interact with cell surface heparin sulfate as a co-receptor (Bloushtain et al., 2004). The 
identified ligand for NKp30 so far is the HCMV tegument protein, pp65 (Arnon et al., 
2005).  
5.5 NK Cells in Anti-Tumor Defense Mechanisms  
The evidence for NK cells role in tumor clearance came from the ''missing self'' 
hypothesis when the MHC class I negative RMA-S cell line was rejected while the same 
parental (positive for MHC class I) was not (Karre et al., 1986). In vivo deficiency 
studies supported NK-dependent rejection of many tumor cell lines (Kim et al., 2000). 
NK rejection of tumors was shown to be dependent on perforin (Van den Broek et al., 
1995 and Smyth et al., 1999), IFNγ (Straat et al., 2001) and TNF-α (Smyth et al., 1998). 
The molecular mechanisms by which NK cells execute their antitumor effect is not 
completely defined. Chronic DNA damage response in tumors results in upregulation of 
NKG2D ligands suggesting a central role for this receptor in tumor control (Gasser et 
al., 2005). NKG2D was also shown to play an essential role in tumor metastasis (Smyth 
et al., 2005). NCRs are also crucial for the killing of tumors by NK cells since NKp46 
blocking in vivo inhibited the NK anti-tumor response toward some melanoma cell lines 
(Pessino et al., 1998). In addition, deletion of the mouse NCR gene in mice diminished 
the ability of NK cells to eliminate tumors (Gazit et al., 2004). Recently, NK cells were  
shown to modulate the innate and adaptive immune response. Active NK cells are 
known to secrete IFNγ, which modulates downstream immune responses (Biron et al.,  
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2001). When IFNγ released into tumor-drained lymph nodes by NK cells it primes a Th1  
response. Naive T helper (Th) cells are activated by recognition of antigens presented 
on antigen-presenting cells (APCs) by the interaction with the T-cell receptor (TCR). 
Upon activation, these effector Th cells can be divided into three main types: Th type-1 
(Th1); Th type-2 (Th2); Th type-17 (Th17) cells, with unique characteristics for each 
type. Th1 cells secrete interferon (IFN)-γ, and (TNF)-β, which is critical for development 
of cell-mediated immune response and consequently tumor cells elimination (Martin-
Fontecha et al., 2004). It was shown that NK cells could behave like APCs through 
antigen uptake and presentation to CD8 T cells (Hanna et al., 2004). In 1999, a report 
showed an interaction between NK cells and DCs (dendritic cells) in anti-tumor 
response (Fernandez et al., 1999). NK cells can activate DCs in the presence of TNF-α 
(Piccioli et al., 2002). In addition, NK cells induce maturation of DCs in vivo, which 
activates CD8+ T cells generating an anti-tumor response (Mocikat et al., 2003). These 
observations suggest that NK cells mediate its anti-tumor role through two independent 
effector and helper pathways. 
5.6 Cancer Immunoediting 
Cancer is a multistep process that represent dysregulation of both oncogenes 
and tumor suppressor genes. Transformed cells acquire genetic and epigenetic 
changes that contribute to the tumor phenotype. In order for normal cells to become 
malignant they exhibit six alterations in their physiology which include; (1) self- 
sufficiency in growth signals, (2) insensitivity to antigrowth signals, (3) limitless 
replicative potential, (4) evasion of apoptosis, (5) sustained angiogenesis (6) tissue  
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invasion and metastasis, (7) reprogramming of cellular energy metabolism, (8) evasion  
of the immune system (Douglas et al., 2011). The ability of the immune system to detect 
and eliminate transformed cells is known as immunosurveillance. Ehrlich’s first 
introduced the concept of immunosurveillance in 1909, when he demonstrated the 
ability of the immune system to identify and destroy tumor cells. Ehrlich’s observation 
was supported 50 years later by Burnet and Thomas when they suggested that 
lymphocytes were responsible for the eradication of continuously arising tumor cells 
(Burnet et al., 1970). Since then a lot of research has been done using a variety of well-
characterized gene-targeted mice, specific immune system activators, and blocking 
monoclonal antibodies highly specific for distinct immunologic components, to identify 
components of the immune system that indeed protect the murine host against tumors 
which include for example IFNγ and effector lymphocytes (T, NK and NKT cells). 
Although the evidence for immunosurveillance depends mainly on mouse models, there 
is evidence that humans also exhibit cancer immunosurveillance. For example, during 
transplantation the immune system of the patients must be suppressed, which results in 
more susceptibility to non-viral cancers. Birkeland et al. showed increased cancer 
incidence for colon, lung, bladder, kidney, ureter, and endocrine tumors in 5692 renal 
transplant patients (Birkeland et al., 1995). In addition, tumor-infiltrating lymphocytes 
(TILs) is a predictor of patient’s five-year survival. Balch et al. analyzed Tumor-
infiltrating lymphocytes from 120 different human cancers, including breast cancer, renal  
cell carcinoma, melanoma, sarcoma, and colon cancer (Balch et al., 1990).  
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 Based on the above, immunosurveillance is a multifactorial process that requires  
the actions of different immune effectors and this diversity is dependent on the tumor's  
type, anatomic localization, tumor stage, tumor’s acquired genetic and epigenetic 
changes, and immunological recognition pattern. Therefore, the immune system could 
promote or eradicate tumors, which is described by a new term, immunoediting. 
Immunoediting could result in (i) Elimination - This phase represents the ability of the 
immune system to eradicate the developing tumor (Figure 5.2).  
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Figure 5.2: A Cartoon Illustrates the Three Phases of the Cancer Immunoediting Process. 
Normal cells (gray) are transformed to tumor cells (red) (top). In the elimination phase, cells and 
molecules of innate and adaptive immunity, may eradicate the developing tumor. However, if elimination 
fails, the tumor cells may enter the equilibrium phase where they may be either maintained chronically or 
edited by the immune system to produce tumor variants that may eventually evade the immune system by 
a variety of mechanisms and enter the escape phase (Dunn et al., 2004). 
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 The elimination phase is initiated by disruption of tissue surrounding the tumor 
because of invasive growth and angiogenesis (Hanhan et al., 1996, Carmeliet et al., 
2000 and Sternlicht et al., 2001). Stromal remodeling is accompanied by pro-
inflammatory cytokines and chemokines production to recruit immune effector cells such 
as NK, T, NKT and /or macrophages to tumor site. The recruited immune cells are 
activated once they recognize their cognate ligands and secrete cytokines such as 
IFNγ, IL-2 and IL-12 that amplify the signal and recruit more CTL to tumor site (Hodge-
Dufour et al., 1997). IFNγ can enhance the expression of tumoricidal products by 
macrophages, enhance NK cytotoxic function toward tumor cells and /or kill tumor cells 
by anti-proliferative, pro-apoptotic and angiostatic effects (Luster et al., 1993, Coughlin 
et al., 1998 and Qin et al., 2000). Dead tumor cells, in turn, become a source of 
antigens that could be directly cross-presented by DC to CD4 Th1 T cells to develop 
tumor specific CD8 T cells (Albert et al., 1998).  
 (ii) Equilibrium - In the equilibrium phase the tumor cells which survived 
the elimination phase enter a dynamic equilibrium with immune cells that exert selection 
pressure on these genetically unstable tumor clones. This phase is the longest of the 
three phases and it might take years for tumor cells in equilibrium to generate clones 
that are poorly recognized either by the immune system or that have acquired 
mechanisms to suppress immune effector functions (Loeb et al., 2005). (iii) Escape - In 
this phase, tumor cells at equilibrium acquire genetic and/or epigenetic modifications to 
avoid the immune system detection and elimination. Mechanisms of evasion include 
release of immunosuppressive factors such as TGF-β (Sakaguchi et al., 2001), induce  
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infiltration of regulatory T cells (Khong et al., 2002), antigenic drift, loss of MHC 
components (Marincola et al., 2000), shedding of ligands that induce cytotoxic activity of 
CTL (Groh et al.,2002) and /or development of IFNγ insensitivity (Kaplan et al., 1998). 
These mechanisms reflect how tumor cells can be edited by the immune system. 
5.7 Breast Cancer & Immunoediting  
Breast cancer is the most common cancer in women, approximately one in eight 
women developing breast cancer during their lifetime. Breast cancer is a heterogeneous 
disease with multiple subtypes and diverse histopathology that results in different 
clinical outcomes (Rosen et al., 2007). Tumor histological grade and tumor type are the 
most important tumor characteristics that can be estimated by histopathological analysis 
of breast cancer. There are many types of breast cancer which include 
adenocarcinomas, micro-papillary, metaplastic, medullary carcinomas and 
inflammatory. Tumor grade is an evaluation of the degree of differentiation, proliferative 
capacity that indicates the tumor's aggressiveness (Elston et al., 1991). Normal breast 
structure is composed of two epithelial layers, the inner luminal epithelium from which 
luminal epithelial breast cancer is derived and the outer basal epithelial layer from which 
the basal-like breast cancer originates. The confinement of breast cancer to breast 
ducts or lobes is referred to as DCIS (ductal carcinoma in situ) and LCIS (lobular 
carcinoma in situ) (Li et al., 2006). Breast cancer can be further classified into subtypes 
based on the incorporation of molecular markers of prognosis and recurrence such as 
ER, PR, Her/2neu and p53 (Silverstein et al., 1995).  
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There is evidence for immunosurveillance in breast cancer supported by the  
presence of CD4, CD8, CD20 and NK cells in DCIS lesions (Macchetti et al., 2006 and 
Czerniecki et al., 2007). This suggest that these effector cells might infiltrate the tumor 
to promote or eliminate the tumor. For example, breast tumors infiltrated with DCs that 
express the CD83 (maturation marker) exhibit prolonged disease-free survival in those 
patients (Czerniecki et al., 2007). However, the presence of CD4, CD8 positive T cells 
or macrophages showed no prognostic significance. The infiltration rate of T cells into 
tumors of patients with lymph node positive breast cancer was significantly increased 
relative to those without lymph node metastases (Macchetti et al., 2006). Similar to 
mouse studies (Knutson et al., 2006 and Santisteban et al., 2009) the presence of CD8 
T cells in human breast cancer has not shown an association with increased survival. 
Some studies showed that increased tumor grade and Ki-67 staining (a marker of 
proliferation) were associated with increased infiltration of CD8, CD4, tumor-associated 
macrophages, and increased tumor angiogenesis. These results could be explained by: 
(i) the active immune response toward poorly differentiated tumors increases tumor 
proliferation, angiogenesis, and dissemination; (ii) high grade tumors secrete many 
cytokines in the tumor microenvironment, which attracts immune cells and increases 
microvessel density (Murri et al., 2008 and Matkowski et al., 2009). Collectively, the 
tumor immunogenicity and its microenvironment will likely dictate the type of infiltrating 
immune cells and their function whether to promote a tumor or impede it. 
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5.8 The NURF Complex 
5.8.1 The Three Main Subunits of NURF Complex and Their Role in Cancer.  
 The NURF complex is a member of ISWI family and consists of the three main 
subunits: bromodomain PHD-finger containing transcription factor (BPTF); the ISWI 
ATPase SNF2L; the WD repeat protein pRBAP46/48 (Xiao et al., 2001and Barak et al., 
2003).  BPTF is the unique and largest subunit of NURF complex and it is crucial for the 
maintenance of complex integrity (Xiao et al., 2001). BPTF contains several conserved 
domains that form platforms for recruitment of modified histones, transcription factors 
and other NURF subunits, which include DDT domain, PHD finger, WAC and WAKZ in 
the N-terminal domain. The DDT domain interacts with the slide domain and this 
interaction is essential for maintaining the complex integrity (Xiao et al., 2001). The 
BPTF subunit has two PHD domains as mentioned above, which has Cys4HisCys3 (4 
cysteines a histidine and 3 cysteines). The C-PHD domain strongly interacts with 
H3K4me3 or 2 while it interacts weakly with H3K4me1 (Wysocka et al., 2006). The 
bromodomain binds acetylated histones (H3K16ac) and cooperate with the C-terminal 
PHD which binds H3K4me3 to facilitate NURF localization to sites in chromatin with 
modified histones (Ruthenburg et al., 2011). 
 SNF2L is essential for both catalytic and remodeling functions of the NURF 
complex. The N-terminal domain of SNF2L includes ATP binding domain and helicase 
domain. The ATP binding domain is enriched with acidic residues that interact with the 
positive residues in the N-terminal tail of H4 to facilitate the NURF remodeling activity 
(Mueller et al., 2013). The C-terminus of SNF2L has three domains, HAND, SANT  
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(Swi3 Ada2-N-cor TfIIIB) and SLIDE (Sant like Domain) (Clapier and Carins et al., 
2009). The HAND domain is required for the interaction with the nucleosomal DNA 
(Dang and Bartholomew 2007). The SANT domain is believed to enable the NURF 
complex to interact with histone H3 (Boyer et al., 2004). The SLIDE domain interacts 
with nucleosomal linker DNA and this interaction is required for the complex remodeling 
activity (Hota et al., 2013).  
RbAp46 and RbAp48 are homologous proteins with WD (Tryptophan-Asparatic) 
repeats that form the platform to facilitate protein-protein interactions to tether the 
remodeler complex to its chromatin. Both proteins act as histone chaperones for histone 
deposition into nucleosomes. RbAp48 interacts with H3-H4 dimer to mediate its 
incorporation into assembled nucleosomes (Zhang et al., 2013). For example, the 
interaction between RbAp46/48 and the transcription factor FOG1 (Friend of Gata1) 
recruit the NURD complex to specific sites of chromatin (Hong et al., 2005). Both 
proteins are also involved in cancer. Overexpression of the RbAp46 in the human 
breast epithelial cells, MCF10AT3B, induced suppression of cell growth in vitro and 
reduced tumor formation in vivo (Li et al., 2003). Similarly, knockdown of the RbAp48 
protein in the cervical cell line, H8, induced tumor formation in nude mice through the 
control of the HPV16 transforming activity (Kong et al., 2007). 
5.8.2 NURF Remodeling Activity 
  As mentioned above, NURF complex subunits involved in protein-protein 
interactions which facilitate the complex remodeling activity by its recruitment to 
nucleosomes. Upon NURF recruitment, it binds the nucleosome at two separate sites,  
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at linker DNA beside the entry site, and the nucleosomal DNA at the exit site. After 
binding, the NURF complex utilizes ATP hydrolysis to move nucleosomes ~ 10bp in 
either direction (Schwanbeck and Wu 2004). The remodeling activity of NURF can be 
regulated by many mechanisms, which include: incorporation of a SNF2L variant that 
produce non-functional ATPase (Barak et al., 2004) or PTM of the NURF complex 
reduces its remodeling function. For example, ISWI acetylation by the histone acetyl 
transferase GCN5 has been thought to reduce the complex remodeling activity (Ferreira 
et al., 2007). In addition, the composition of the histone octamer and nucleosome 
structure can modulate the NURF activity. For example, the incorporation of the histone 
variant H2AZ enhances ATP hydrolysis ~9 fold greater than H2A and increases its 
remodeling activity (Goldman et al., 2010). Collectively, the NURF remodeling activity is 
affected by incorporation of an inactive ATPase, histone variants or the PTM of the 
complex (Alkhatib and Landry, 2011). 
5.8.3 The Biological Roles of NURF Complex 
 The NURF complex interacts with many transcription factors and DBPs with 
consequences on gene expression and function (Xiao, et al. 2001). In Drosophila, 
NURF is required for the expression of homeotic genes and its disruption affects the 
determination of body segments (Badenhorst, Voas, et al. 2002). In addition, NURF is a 
co-activator of the Wingless pathway through its interaction with the pathway signal 
transducer β-Catenin/Armadillo, which is a transcription factor that recruit NURF to 
promoters of Wingless downstream genes to initiate their expression (Song, Spichiger-
Haeusermann and Basler 2009). NURF is essential for self-renewal and maintenance of  
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germline stem cells through its positive regulation of the JAK/STAT pathway  (Cherry 
and Matunis 2010). In human breast cancer cell lines, BPTF interacts directly with PR 
(progesterone receptor) to recruit NURF, which in turn recruits other co-activators to 
promote gene expression (Vicent, et al. 2011). 
As a chromatin remodeler, NURF is involved in the regulation of the chromatin 
structure. NURF directly interacts with the histone chaperone Nap1 to regulate 
nucleosomes assembly at heterochromatin domains (Stephens , et al. 2006). NURF is 
also, involved in the separation between euchromatin and heterochromatin regions. In 
chicken erythroleukemia cell lines USF1 interact with NURF to mediate its recruitment 
to the HS4 element of the β-globin insulator. HS4 element is required to prevent the 
heterochromatin from disrupting β-globin locus expression (Li, et al. 2011). In addition, 
recent work in our lab supports the role of NURF in regulation of chromatin structure. 
CTCF is the main insulator in vertebrates with roles in chromatin looping to enhance 
gene expression like the ring-like structure cohesion. Insulators are DNA-protein 
complexes, which prevent enhancer-promoter interactions and/or form barriers to 
isolate the silencing effects of heterochromatin (Jingping et al., 2011). NURF interacts 
with both CTCF and cohesion suggesting a possible role in chromatin looping and 
organization  (Qiu, et al. 2015). 
  In mammals, NURF is essential for early embryonic development since KO of 
the complex’s essential subunit (BPTF) resulted in early embryonic lethality. BPTF KO 
embryos fail to gastrulate due to defective DVE differentiation, which could be due to its  
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co-activation role of the TGF/Smad pathway. Moreover, BPTF KO mESCs were 
defective in their differentiation potential, which is supported by the defective 
differentiation of embryoid bodies and teratoma in vitro (Landry et al., 2008). This 
observation was further verified by investigating the role of NURF in T cell development. 
Thymocyte maturation is accomplished by TCR (T-cell receptor) pathway to determine 
the lineage specification of a double positive cell that express both CD8 and CD4 to be 
a single positive cells that express CD8 or CD4. Thymocytes isolated from BPTF KO 
mice exhibited normal proliferation rate but fail to specify their lineage, which suggest 
the NURF role as cell type-specific regulator of gene expression (Landry, et al. 2011).  
5.8.4 NURF and Cancer 
 BPTF and by extension NURF is located on chromosome 17 at q24.2, this region 
is amplified in many cancers including  neuroblastoma (Bown, et al. 1999), breast 
cancer (Monni, et al. 2001), prostate cancer (Levin, et al. 2008), liver cancer (Raidl, et 
al. 2004) and lung cancer (Choi, et al. 2006), which suggest advantageous role for this 
region to tumor survival. BPTF overexpression is associated with more aggressive 
disease in HCC (hepatocellular carcinoma) and colorectal cancer (Xiao, Liu and Fang, 
et al. 2015). BPTF overexpression in melanoma is associated with poor prognosis, in 
addition, KD of BPTF reduced proliferation rate of melanoma cell lines both in vitro and 
in vivo (Dar, et al. 2015). C-myc is a proto-oncogene that is deregulated in many 
cancers (Vita et al., 2006). Recently, Richart et al. showed that BPTF is a co-partner of 
c-myc to regulate the transcription program of c-myc in MEFs and in vivo depletion of 
BPTF reduced tumor growth (Richart et al., 2015). Recent work in our lab revealed that 
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BPTF knock-down enhance tumor immunogenicity by directly regulating the 
immunoproteasome subunits Psmb8 and Psmb9, Tap1 and Tap2, which enhance 
antigen presentation and production (Mayes et al., 2016). 
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Chapter 6 
Material and Methods 
6.1 Cell Culture 
67NR, 66cl4, 4T1 (Fred Miller, Wayne State University) and SY5Y, HeLa, HEK 
293T (ATCC) were cultured in DMEM (Thermo-Fisher), 10% FBS (Hyclone), 1% NEAA 
(Thermo-Fisher), 1% glutamine (Thermo-Fisher), and 1% penicillin/streptomycin 
(Thermo-Fisher). T47D and MDA-MB-436 were cultured in RPMI (Thermo-Fisher), 10% 
FBS, 1% NEAA, 1% glutamine, 1% penicillin/streptomycin and 5 µg/ml insulin (Sigma). 
NK-92 cells (ATCC) were cultured in Alpha MEM (Thermo-Fisher), 12.5% horse serum 
(Sigma), 12.5% FBS, 2 mM L-glutamine, 1.5 g/L sodium bicarbonate (Sigma), 0.2 mM 
inositol (Sigma), 0.1 mM β-mercaptoethanol (Sigma), 0.02 mM folic acid (Sigma) and 
200 U/ml Il-2 (R&D Systems). OT1 T cells were cultured in DMEM containing 10% FBS, 
1% NEAA, 1 % glutamine, 1% penicillin/streptomycin, 1% HEPES (Thermo-Fisher), 50 
µM β-mercaptoethanol and 500 U/ml mouse IL-2.  
6.2 Western Blotting  
Monolayer cells, cell pellet or collected tumors homogenate were homogenized 
by pipetting using 1 ml pf TRI-Reagent for 5 min. The homogenates were incubated with 
200 μl chloroform for 15 min. Then, samples were centrifuged for 15 min at 20,000 RCF 
at 4°C. Three layers were formed; an aqueous phase contains the RNA, an interphase 
contains the DNA and an organic phase contains the proteins (bottom layer). After 
removing the aqueous and interphase, 1 ml isopropanol was added to samples and the 
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tubes were incubated at room temperature for 10 min. Then, the samples were 
centrifuged at 20,000 RCF for 15 min at 4°C.  The supernatants were discarded and 1 
ml of 0.3 M guanidine in 95% ethanol was added for overnight wash at 4°C on shaker. 
Then, the guanidine was removed by centrifugation at high speed and protein pellets 
were washed overnight with 1 ml of 100 % ethanol at 4°C on shaker. Next, proteins 
were dissolved in 250 μl of 8 M urea in 1% SDS at 65°C overnight.  Protein 
concentration was measured using Bio-Rad Dc Protein Assay provided by Bio-Rad 
Laboratories (Hercules, CA) using BSA standards. 50 μg of protein was loaded into 4% 
SDS-PAGE, and run for 1 hour at 200 V and 300 mA.  Next, proteins were transferred 
into PVDF (polyvinylidene fluoride) membrane for 17 hours at 20 V and 30 mA. Transfer 
buffer for Ino80 was 10 mM CAPS-NaOH [ph10.5] and 2.5 mM DTT. After transfer, the 
PVDF membranes were blocked with 5% non-fat dry milk for 1 h, and incubated with 
primary antibody for overnight at 4°C. Primary antibodies used in this study include; 
BPTF (custom rabbit  polyclonal) at 2 µg/ml; anti-heparanase (Santa Cruz Cat# 
sc25826) at 1 µg/ml; anti-HS (Millipore Cat# MAB2040) at 2µg/ml. Next, membranes 
were washed three times with PBST (phosphate buffer saline with 0.1% tween 20) for 
10 min each, and the membranes were incubated with horseradish peroxidase (HRP)-
conjugated anti-rabbit or anti-mouse secondary antibody (Cell Signaling) at 0.1 µg/ml for 
1hour. The plots were then washed for 10 min with PBST for three times and developed 
using Super Signal West Femto Substrate (Thermo Scientific). 
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6.3 BPTF KD (in OT1 & NK Cells Using Replication-Deficient Adenovirus) 
 Spleens from OT-l mice were harvested and dispersed into single cell 
suspensions in MACS buffer and erythrocytes were removed by suspension in RBC 
lysis buffer. The cells were then washed, suspended in DMEM containing 10% FBS, 1% 
NEAA, 1% glutamine, 1% penicillin/streptomycin, 1% HEPES, 50µM β-mercaptoethanol 
(Sigma) and 500 U/ml mouse IL-2 (R&D Systems), and co-incubated with mitomycin C-
treated B16F10-OVA cells for 3 weeks with continuous medium change until we got a 
high population of OT1 T cells. 3X106 NK-92 or 5X105 OT1 T cells were infected with 
2X107 rADV or 2X106 in a volume of 10 ml or 1 ml for 5 days and then collected for 
Western blot analysis. Remaining cells were used for cytotoxicity assays as described 
below. 
6.4 Tumor Studies 
1x105 67NR cells, 1x104 66cl4 cells or 1X105 4T1 cells were injected into the 
fourth mammary fat pad of BALB/cJ or NSG mice. Tumors were analyzed at 21 days 
(67NR), 28 days (66cl4) or 35 days (4T1). For rADV studies, BALB/cJ mice were 
inoculated with 1x106 66cl4 or 3x105 4T1 cells and injected intratumorally with rADV-Luc 
or rADV-BPTF (1 × 109 PFU in 100ul) every 3 days for 3 weeks once tumors were ~5 
mm in any dimension. Animals were euthanized 1 week after the last injections and 
tumors were collected for analysis. For all 4T1 studies, mice were injected I.P. with 1.2 
mg/mouse gemcitabine 5 days after tumor inoculation and once every 7 days thereafter. 
The mice used in these studies were BALB/cJ (Jackson Laboratories Cat# 000651) and  
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NOD/SCID/Ifrg2r -/- (NSG) (Jackson Laboratories Cat# 005557) female mice 6-8 weeks 
of age were housed under aseptic barrier conditions. The Institutional Animal Care and 
Use Committee at Virginia Commonwealth University have approved these studies. 
6.5 Mouse NK Cells Purification 
The spleens of BALB/c mice and NK cells were purified by negative selection 
using a magnetic separation MACS column (Miltenyi Biotech, cat# 130-690-864.). The 
spleens were cut and pressed gently to release the splenocytes. The splenoctytes were 
collected with 5 ml of MACS column buffer (PBS [pH 7.2], 2 mM EDTA, 0.5% BSA) and 
passed through a 0.45 μm filter to create a single cell suspension. The cells were 
counted and centrifuged for 10 min at 300 x g before resuspending into 400 μl of buffer 
per 1 x 108 cells. 100 μL of a primary biotin-conjugated antibody cocktail (Miltenyi 
Biotec) was added per 1 x 10^8 cells and incubated on ice for 20 min. This cocktail 
binds all non-NK cells. 300 μL of buffer was subsequently added followed by 200 μL of 
secondary magnetic microbead-strepavidin antibody per 1 x 108 cells and incubated for 
10 min on ice. The samples were then washed with 4 mL of buffer per 108 cells and 
centrifuged for 10 min at 300 x g. After carefully aspirating the supernatant, the cells 
were resuspended into 500 μL of buffer per 1 x 108 cells and separated on MACS LS 
columns (Miltenyi Biotec). The LS columns pre-rinsed with 3 mL of buffer before adding 
500 μL of the prepared splenocytes suspension. Following this, 3 mL of buffer was 
added to the column to elute the unlabeled NK cells, while the column retained the 
biotin-labeled cell fractions. NK cells were eluted using three additions of buffer. The  
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eluted NK cells were centrifuged for 10 min at 300 x g and resuspended into 2 mL of 
complete RPMI-10 medium (10% FBS, 2 mM glutamine, 1x penicillin-streptomycin, 50 
μM β-mercaptoethanol and 50 U/ml IL-2) and counted. 
6.6 NK Cell Cytotoxicity Assay 
 NK 92 cells were cocultured with the targets, which were plated at the indicated 
E:T ratios for 4 hrs. For antibody blocking experiments, NK cells were pre-incubated for 
1 hr with blocking antibodies to hNKp46 (Biolegend Cat# 13614), hNKp30 (Biolegend 
Cat# 325204) or hNKG2D (BD Pharmingen Cat# 552866) at 10 µg/ml. NK cells were 
then plated on mitomycin C treated cells for assay. Cell death was measured using the 
CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega). The plate was then 
placed on a plate reader and the wells were read at 490 nm absorbance for LDH 
release by spectrophotometer (Synergy H1 Multi-Mode Plate Reader, BioTek). Percent 
cytotoxicity was calculated using (Experimental – Effector Spontaneous – Target 
Spontaneous)/ (Target Maximum – Target Spontaneous) x 100. 
6.7 Flow Cytometry  
 To measure NK activity, purified mouse splenic NK cells were incubated with 
mitomycin C treated cells for 24 hours. NK cells were removed and stained with BD 
Pharmagen antibodies; 0.25 µg anti-NKp46 (FITC), (Cat# 137605); 0.1 µg anti-CD69 
(PE), (Cat# 561932) and 7AAD viability dye. 
 For tumor infiltrating lymphocyte analysis, tumors were minced and digested in 
0.04% DNase 1, 0.1% collagenase IV (Sigma) at 37°C for 30 min. Tumor digests were 
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filtered with a 40 µM nylon filter and centrifuged at 500 x g for 5 min at room 
temperature. Cells were resuspended in 40% percoll (Sigma), layered on top of 70% 
percoll and centrifuged at 3000-x g for 30 min at room temperature. Lymphocytes at the 
interphase were removed, diluted in PBS, and centrifuged at 500 x g for 5 min at room 
temperature. Cells were stained with BD Pharmagen antibodies: 0.25 µg anti-NKp46 
(FITC), (Cat# 137605); 0.1 µg anti-CD69 (PE), (Cat# 561932); 0.25 µg anti-CD3 (PE), 
(Cat# 553060); 0.25 µg anti-CD8 (FITC), (Cat# 100706) antibodies and 0.5 µg 7AAD 
viability dye. 
  For the Ncr1-Ig fusion protein was purified by protein G chromatography from 
the culture supernatant of stably transfected HEK293 cell line (gift from Ofer 
Mandelboim). 1X105 Cells were incubated with 5 µg of the soluble receptor for 45min at 
4°C, washed, stained with PE- anti-Human-IgG Fc (Biolegend Cat# 409304) for 20 min 
and analyzed by flow cytometry using a FACS Calibur flow cytometer (Becton 
Dickinson).  
6.8 Enzyme Linked Immunosorbent Assay (ELISA)  
 Tumors were minced with a clean razor blade and placed in HBSS supplemented 
with complete protease inhibitor (Roche). After 3 of freeze-thaw cycles, samples were 
centrifuged at 15000 x rpm at 4°C for 15 min supernatant was collected and tested for 
total protein using a DC protein assay kit (Biorad). ELISA for IFNγ was performed 
according to the manufacturer's instructions (R&D systems). IFNγ concentrations was 
then normalized to total protein. 
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6.9 Ncr1- ζ Chain Reporter Assay 
 Murine BW thymoma cells (TCR α/β negative) were transfected with constructs 
encoding chimeric proteins in which the extracellular portion, which has the ligand 
binding domain of NKp46 is fused to the transmembrane and tail domains of the 
CD3 ζ chain. The cytoplasmic domain of the T-cell receptor ζ-chain is sufficient to trigger 
IL-2 secretion upon ligation of extracellular portion of NKp46 to its cognate ligand (Gili et 
al., 2009). To measure the levels of NCR1 and its ligands expressed by target tumor 
cell lines, BW Ncr1-ζ and target cell lines were co-incubated at 1:1 E: T ratio for 48 h at 
37°C and 5% CO2. Total RNA was extracted from cultured cells with TRI Reagent and 
5 µg RNA was reverse transcribed using Superscript II First-Strand Kit (Invitrogen). 
qRT-PCR was performed using SYBR green PCR master mix (Biorad) with a 7900 HT 
Fast Real-Time qPCR System (Applied Biosystems). The ∆∆CT method was performed 
using normalization to GAPDH. Primer pairs are provided in Table 6.1 
Table 6.1: Primers Used for IL-2 qRT-PCR 
NCR1-Zeta IL2 Reporter Assay Primers  
NCR1  For GAGGATCAACACTGAAAAGGAGAC 
 Rev ACTCTGCTTGGATGTTCCCA 
IL- 2  For CCTGAGCAGGATGGAGAATTACA 
 Rev TCCAGAACATGCCGCAGAG 
 
6.10 qRT-PCR 
qRT-PCR was performed as described in chapter two. Primers used for heparanase 
quantification are provided in Table 6.2. 
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Table 6.2: Primers for Heparanase Quantification  
Heparanase qRT-PCR Primers 
mGapdh  For TGGCAAAGTGGAGATTGTTGCC 
 Rev AAGATGGTGATGGGCTTCCCG 
mHeparanase   (67NR) For GAGCGGAGCAAACTCCGAGTGTATC 
 Rev GATCCAGAATTTGACCGTTCAGTT 
mHeparanase  (66cl4) For GGAAATCTCAAGTCAACCATGATAT 
 Rev ATCTCCACTGAGCTTCTTGAGTAG 
 
6.11 Chromatin Immunoprecipitation (ChIP) 
ChIP was performed as described in chapter two and primers used for 
heparanse promoter are provided in Table 6.3. 
Table 6.3: Primers for Heparanae ChIP Analysis 
Heparanase ChIP Primers 
Promoter Site  For GGTGGCCAGAATCCAAGATCC 
 Rev AAAAACAGGGTCCCCACCAC 
 
6.12 Statistics 
 Standard deviation was used to calculate error bars throughout the study. P 
values were calculated using two tailed T tests. Number of replicates are designated in 
the repetitive figure legends. 
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Chapter 7 
Results 
 
7.1 BPTF Depletion in Tumors Enhances NK Cell Antitumor Activity 
 To uncover the possible role for BPTF in breast cancer biology, we transduced 
the well-established 67NR and 66cl4 mouse breast cancer cell lines (Aslakson and 
Miller, 1992) with retroviruses expressing control (Ctrl-sh1, Ctrl-sh2) or BPTF (Bptf-sh1, 
Bptf-sh2) short hairpin RNAs (Figure 7.1 A). Both Ctrl and BPTF KD 66cl4 and 67NR 
cell lines were inoculated into the 4th mammary fat pad of syngeneic BALB/c mice and 
tumors were collected 3-4 weeks later and tumor weights were assessed. We observed 
a significant reduction in BPTF KD tumor weight compared to controls (Figure 7.1 B). 
Microarray analysis of control and BPTF KD tumors discovered an enrichment of genes 
with gene ontology (GO) terms that included immune response genes (data not shown) 
suggesting a possible role for the immune system in the BPTF KD reduced tumor 
weight. To validate our hypothesis, we have inoculated both Ctrl and BPTF KD 66cl4 
and 67NR cell lines into an immune-deficient NOD/SCID, Ifrg2r -/- (NSG) background. 
Both Ctrl and BPTF KD 66cl4 and 67NR cell lines showed equivalent tumor weights to 
controls, suggesting an immune response toward BPTF KD tumors (Figure 7.1 C). 
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Figure 7.1: NK Cells Are the Key Effectors in BPTF KD 67NR and 66cl4 Tumor Weight Reduction.  
A) BPTF Western blot analysis from control (Ctrl-sh1, Ctrl-sh2) and BPTF KD (Bptf-sh1, Bptf-sh2) 67NR 
and 66cl4 total cell extracts. Membranes were stained with Ponceau as a loading control.  
B) 67NR and 66cl4 tumor weights harvested from BALB/c mice. Control and BPTF KD cells were injected 
subcutaneously into the fourth mammary fat pad of BALB/c mice and tumors were weighed on day 21 
(67NR) or day 28 (66cl4) (n ≥ 11, * = t-test p-value < 0.0005).   
C) 67NR and 66cl4 tumor weights harvested from NSG mice (n = 9).  
D&E) 67NR and 66cl4 tumor weights harvested from undepleted, or CD8+, CD4+ or asialo-GM1+ mAb    
depleted BALB/c mice (n = 6, * = t-test p-value < 0.05). 
              This figure is done by Suehyb Alkhatib and Kimberly Mayes. 
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The immune system executes its elimination function against tumors using 
immune effector cells. These immune effector cells infiltrate the tumor tissue to lyse 
tumor cells. Lymphocytes populations have been identified in breast cancer, which 
include (CD8+) T cells, helper (CD4+) T cells and NK cells (Whitford et al., 1992 and 
Chin et al., 1992). To characterize the main effector immune cells that are involved in 
BPTF KD reduced tumor weights, we depleted the major immune effector cells in mice 
that have been inoculated with both Ctrl and BPTF KD  66cl4 and 67NR cell lines using 
monoclonal antibodies against NK cells, CD8+ T cells, or CD4+ T cells. Depletion of 
CD8+ T-cell or CD4+ T-cell did not reduce the weight BPTF KD tumors (Figure 7.1 D, 
E). However, NK cell depletion resulted in approximately equal tumors weight in both 
Ctrl and BPTF KD 67NR and 66cl4 cell lines. These results suggest that NK cells are 
the major effector immune cells that are responsible for the reduced BPTF KD tumor 
weight. 
 To quantify and characterize the NK cell population in the tumor 
microenvironment (TME), we have conducted flow cytometry analysis on lymphocytes 
isolated from both Ctrl and BPTF KD 67NR and 66cl4 tumors. The gating strategy is 
illustrated in (Figure 7.2 A, C). To evaluate the abundance of lymphocytes in the TME, 
we stained lymphocytes with CD3 and NKp46 to select for the CD3- and NKp46+ 
population. We used the CD3 marker to exclude the NKT cell population that express 
NKp46 on their cell surface. As shown in (Figure 7.2 B) the rate of NK cells infiltration 
was very high in these tumors. To eliminate the possibility of non-specific staining, we 
repeated the same experiment using 4T1 tumors that are known to be poorly infiltrated 
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with NK cells (duPre et al., 2008). To assess the activation status of NK cells we used 
CD69, a known marker for lymphocytes activation. As shown in (Figure 7.2 D), that NK 
cell abundance in the TME was approximately equal in both Ctrl and BPTF KD 67NR 
and 66cl4 tumors. However, NK cells in BPTD KD TME were more active than those in 
Ctrl tumors (Figure 7.2 D). These results demonstrate that BPTF KD cells enhance NK 
cytotoxic activity, which could result in the observed reduced tumor weight. 
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Figure 7.2: NK Cells Are More Active in the BPTF Depleted Tumor Microenvironments. 
A) Representative flow cytometry dot plots of live tumor infiltrating NK cells stained with CD3ε and NCR1.  
B) Percentages of live CD3-, NCR1+ NK cells from of all live lymphocytes isolated from tumors (n ≥ 6).  
C) Representative flow cytometry dot plots of live tumor infiltrating NK cells stained with CD69 and NCR1.  
D) Percentages of live NCR1+ cells that are CD69high (n = 6, * = t-test p-value < 0.006). 
             This figure is done by Mark Roberts and Zeinab Elsayed. 
 
 
 
 
 
 
 
 
 
  
  
    
  
 
108 
 
7.2 BPTF Depletion in Cancer Cells Enhances NK Cell Cytotoxic Activity in Vitro 
Through NCR Receptors 
The ability of NK cells to kill BPTF KD cells in vivo suggests that BPTF KD cells 
are better targets than Ctrl cells for NK cells and enhance their cytotoxicity. To verify 
this observation in vitro we cocultured the purified splenic mouse NK cells with both Ctrl 
and BPTF KD 67NR and 66cl4 cells. Results showed that NK cells are more active 
when cocultured with BPTF KD targets as was indicated by the elevated expression of 
cell surface activation markers CD69 and NKp46 (Figure 7.3 A, B). The question now, 
how BPTF KD targets enhance NK cytotoxic activity. The most likely explanation is that 
BPTF KD cells overexpress or downregulate activating or inhibitory NK receptor ligands, 
respectively. However, NK cells have a hundred of activating and inhibitory receptors, 
which make it difficult to screen the ligands of all these receptors on the cell surface of 
BPTF KD targets.  
In an attempt to narrow down our possible ligands, we have tested the ability of 
the human NK-92 cells to lyse both Ctrl and BPTF KD targets. NK-92 cells are IL-2-
dependent human cell line that expresses high levels of activating receptors (NKp30, 
NKp46, 2B4, NKG2D and CD28), high levels of cytotoxic molecules such as perforins 
and granzymes, and few inhibitory receptors (Guitta et al., 2000). The number of major 
killing receptors that are involved in cancer elimination and conserved between NK-92 
and naïve mouse NK cells are limited. Towards this end, we co-cultured our NK-92 cells 
with both Ctrl and BPTF KD targets and measured the cytotoxic effect of NK-92 cells. 
As illustrated in (Figure 7.3 C), NK-92 cells showed significantly more cytotoxic effects  
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toward BPTF KD targets compared to controls. These same results were observed 
using native mouse NK cells (data not shown). These results in combination suggest 
that NK-92 cytotoxic activities toward BPTF KD targets is due to a conserved cell 
surface receptor on both NK-92 and mouse naïve NK cells.  
To identify the receptor on NK-92 which recognizes a BPTF-dependent ligand, 
we have blocked the major activating receptors on NK-92 cells using monoclonal 
antibodies against NKp46, NKp30 and NKG2D. The results showed that NKp30 
blocking significantly diminished the NK-92 cytotoxic activity toward BPTF KD 66cl4 
(Figure 7.4 A-C). NKp30 is highly expressed on NK-92 and it is also the major NCR 
used by NK92 cells for antitumor activity (Maki et al., 2001). Also, NKp46 reduced NK-
92 cell activity but the results were not statistically significant. However, blocking of 
NKG2D has almost no effect on NK-92 cytolysis. These results demonstrate that NCRs 
are the major receptors involved in the killing of BPTF KD targets. 
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Figure 7.3: A Cell Surface Factor Enhances Mouse NK Cells and NK-92 Cells Activation Toward   
BPTF Depleted Tumor Cells.  
A) Representative flow cytometry dot plot and percentages of live mouse NK cells stained with NCR1 and     
CD69 after coculture with 67NR or 66cl4 targets at a 5:1 E: T ratio (n = 3, * = t-test p-value < 0.04). 
B) Fold change of NCR1 MFI on mouse NK cells after co-culture with 66cl4 or 67NR target cells at a 5:1 
E: T ratio. (n ≥ 4, * = t-test p-value < 0.05). 
C) NK-92 cells were cocultured with 67NR and 66cl4 at the indicated E: T ratios (n = 3, * = t-test p-value < 
0.05). 
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Figure 7.4: NKp30 is Required for BPTF KD Targets Killing by NK-92 Cells in vitro. 
A) Cytolytic activity of NK-92 cells non-treated or pretreated with anti-NKp46 using the LDH assay,  
B) Cytolytic activity of NK-92 cells non-treated or pretreated with anti-NKp30 using the LDH assay, 
C) NK-92 cells non-treated or pretreated with anti-NKG2D mAb when cocultured with control or BPTF KD 
66cl4 targets at a 10:1 E: T ratio (n = 3, * = t-test p-value < 0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C 
  
  
    
  
 
112 
 
 
 
To verify our observation, we repeated our cytotoxicity assay in the presence of 
heparin. Soluble heparin is known to inhibit NCRs binding to their ligands on tumor cells 
and enhancement of NK cells activity. When BPTF KD targets cocultured with NK-92 
cells in the presence of heparin, NK-92 cytotoxic activity was significantly reduced, 
which further supports that NKp30 is the NK-92 receptor that enhances their cytolysis 
activity toward BPTF knock-down targets (Figure 7.5 A, B).  
NKp46, and its mouse orthologue NCR1, are important activation receptors that 
are involved in the killing of tumor cells in vitro and in vivo (Sivori et al.,1999, Sivori et 
al., 2000 and Gili et al., 2009). It has been shown that the proximal domain of NCR1 is 
the ligand binding domain that activates NK cells degranulation upon engagement (Alon 
et al., 2005). The fusion of this domain to the FC portion of the human IgG have been 
widely used to identify the receptor ligands (Gazit et al., 2006).  
In order to assess the levels of NKp46/NCR1 ligands on the surface of both Ctrl 
and BPTF KD 67NR and 66cl4 cell lines, we stained cells with recombinant NCR1-Fc 
receptor. Flow cytometry analysis revealed equal binding of NCR1 in both Ctrl and 
BPTF KD cells (Figure 7.5 C). Based on cytotoxicity assay results that exhibited more 
NK cytotoxic activity toward BPTF KD targets suggests the presence of more activating 
ligand on BPTF KD targets. We explored the ability of both Ctrl and BPTF KD targets to 
induce IL-2 expression in BW reporter cells.  
The BW cells are a mouse thymoma cell line that lack the expression of α and β 
of TCR chains and can be induced to secrete IL-2. When the NCR1 ligand binding  
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domain is fused to the CD3-ζ chain and stably expressed in BW cells, the chimeric 
protein can induce the expression of IL-2 upon ligand binding (Gili et al., 2009). As 
shown in Figure 7.5 D, co-incubation of both Ctrl and BPTF KD target with BW cells 
resulted in higher expression of IL-2 in BPTF KD targets, suggesting the presence of a 
functional NCR1 ligand on the cell surface of BPTF KD cells. 
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Figure 7.5: NK Cell Cytolysis Activity to BPTF KD Cells Requires NCR Receptors. 
     A and B) Percent target cell cytotoxicity as measured by LDH assay. NK-92 cells were cocultured with 
67NR or 66cl4 targets at a 5:1 E: T ratio with or without heparin. (n = 3,* = t-test p-value < 0.05). 
C) Representative flow cytometry histograms of NCR1-Ig binding to 67NR and 66cl4. 
D) qRT-PCR analysis of IL-2 expression in Ncr1-ζ, IL-2 reporter BW cells incubated with control or BPTF   
KD 66CL4 and 67NR cell lines for 48 hrs (n ≥ 3, * = t-test p-value < 0.05). 
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7.3 BPTF Regulates Cell Surface HS Abundance on HSPG and Heparanase 
Expression. 
 HS (heparin sulfates), also known as HSGAGs (heparin sulfate 
glycosaminoglycans), are members of the glycosaminoglycan family. HS are complex 
polysaccharides that are characterized by a repeat disaccharide unit of iduronic or 
glucuronic acid linked to a glucosamine. When the HS are covalently attached to 
proteins, they are called heparin sulfate proteoglycans (HSPGs). Although HS are 
expressed on the cell surface of both normal and tumor cells, their fine structure and 
sequence are modulated in both cell types to play diverse roles (Ram et al., 2002). It 
has been shown that the presence of HS on tumor cells induce NK cytotoxic activity 
through engagement with NCRs (Hershkovitz et al., 2008 and Hecht et al., 2009). Our 
microarray data (data not shown) revealed alteration in HS metabolism genes, which 
encouraged us to look at the levels of HS on the cell surface of both Ctrl and BPTF KD 
cells. As expected, the levels of HS were upregulated on the surface of BPTF KD 67NR 
and 66cl4 targets when compared to Ctrl cells (Figure 7.6 A) suggesting that high levels 
of HS on the surface of BPTF KD cells enhance NCR engagement and activate NK cell 
cytotoxicity.  
Heparanase is an endo-glycosidase that cleaves the HS side chain of HSPGs on 
the cell surface. Heparanase is overexpressed in human tumors such as breast cancer 
(Gomes et al., 2013), hepatocellular carcinoma (El-Assal et al., 2001) and gastric 
cancers (Endo et al., 2001). Since it plays important roles in metastasis, angiogenesis 
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and inflammation. The levels of heparanase affect many physiological processes in the 
cell so its expression is tightly regulated (Nta et al., 2006).  
So far, heparanase is the only known mammalian enzyme to regulate the levels 
of HSPGs on cell surface (Fuxt al., 2009 and Caruana et al., 2015).  In an attempt to 
identify BPTF regulated genes that are involved in the regulation of HS on cell surface. 
We investigated the levels of heparanase using qRT- PCR and Western blot analysis. 
As shown in Figure 7.6 B, C, the levels of heparanase are substantially downregulated 
at both the levels of RNA and protein in BPTF KD 67NR and 66cl4 when compared to 
Ctrl. These data suggest that BPTF could directly regulate the levels of heparanase. To 
test this hypothesis, we have conducted ChIP experiment, which revealed heparanase 
promoter occupancy by BPTF supporting a direct role for BPTF in regulating the levels 
of heparanase in 67NR and 66cl4 cell lines (Figure 7.6 D) (Kuo and Allis, 1999).  
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Figure 7.6: BPTF Regulates Heparanase Expression 
A) HSPG Western blot analysis of cell surface extracts using anti-HS primary mAb. Arrows indicate 
reproducible changes in HSPG abundance with BPTF KD. 
B) Heparanase Western blot analysis of cell surface extracts from control and BPTF KD cell lines. 
C) qRT-PCR analysis of heparanase (HPSE) expression from 67NR and 66cl4 cells (n = 3, * = t-test p-
value < 0.006). 
D) BPTF ChIP at the mouse heparanase’ promoter (n = 3, * = t-test p-value < 0.04). 
           This figure is done by Kimberly Mayes.  
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7.4 BPTF Depletion Enhances the Immune Response to Established Tumors 
 In our transplantation experiments, we have used cell lines that constitutively 
express BPTF-shRNAs. Therefore, we decided to determine the antitumor effect of 
BPTF KD in established tumors. Toward this end, we constructed a replication-deficient 
adenovirus (rADV) expressing control or BPTF KD shRNAs. The ability of rADV to 
efficiently KD BPTF in both 66cl4 and 4T1 cells was first demonstrated in vitro (data not 
shown). Both 66cl4 and 4T1 cell lines were inoculated into BALB/c and once the tumors 
reached a palpable size (~5 mm), we started an intra-tumor injection with 1x109 PFU 
rADV of either virus, three times a week for three weeks. BPTF levels in established 
tumors were reduced in response to rADV treatment as measured by Western blotting 
(Figure 7.7 A). BPTF KD in those tumors resulted in significant reduction in tumor 
weight (Figure 7.7 B) and in some cases to complete tumor regression in 66cl4 tumors. 
To evaluate the anti-tumor effect of BPTF KD, we measured the levels of infiltration and 
activation of NK cells in 66cl4 tumors and CD8+ T cells 4T1 tumors, respectively. We 
previously showed that BPTF KD enhances the CD8+ T cell response to 4T1 tumors 
because of improved tumor antigenicity (Mayes et al., 2016). BPTF KD in established 
tumors enhanced both NK and CD8+ T cells’ activity (Figure 7.7 C).  
 Active immune effector cells are characterized by cytokine secretion such as 
IFNγ that modulate TME. To assess the ability of active of NK and CD8+ T cells for 
cytokine secretion, we measured the levels of IFNγ in the TME. As illustrated in Figure  
7.7 D, BPTF KD tumors exhibit high levels of IFNγ demonstrating a conversion to a Th1 
TME. rADV injection into established tumors could KD BPTF in tumor and non-tumor  
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cells. To monitor the effect of BPTF KD on NK cells and CD8 T cells, we transduced 
NK92 cells and splenic mouse OT1 T cells with rADV to knock-down BPTF, which was 
verified by Western blot analysis (Figure 7.8 A, C). After BPTF KD in NK-92 and OT1 T 
cells, we measured their cytolytic activity in vitro. Results showed that BPTF KD did not 
alter NK cells or T cell cytotoxic activity (Figure 7.8 B, D) indicating that rADV treatment 
of established tumors did not compromise effector cell function. 
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Figure 7.7: BPTF is Required for an Immune Suppressive Tumor Microenvironment.  
A)BPTF Western blot analysis of 66cl4 and 4T1 tumors injected with replication-deficient adenovirus 
(rADV) expressing either control (Ctrl-sh) or BPTF KD (Bptf-sh) shRNAs.  
B) Weights of 66cl4 and 4T1 tumors after treatment with rADV (n ≥ 6, * = t-test p-value < 0.003).  
C)Flow cytometry analysis of 66cl4 tumor infiltrating NK cells and 4T1 tumor infiltrating CD8+ T cells. 
Active lymphocytes are quantified as percent CD69high of total infiltrating NK cells (NKp46+) or CD8+ T 
cells (CD8+) (n ≥ 4, * = t-test p-value < 0.01).  
D) IFNγ concentrations from 66cl4 and 4T1 tumor extracts measured by ELISA (n ≥ 6, * = t-test p-value < 
0.04). 
             This figure is done by Mark Roberts and Zeinab Elsayed.  
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Figure 7.8: BPTF is Not Required for NK or CD8+ T Cell Cytolytic Activity.  
  A and C) BPTF Western blot analysis on total cell extracts from control and BPTF KD NK-92 or (c) 
mouse    OT1 T cells after rADV infection.  
 B and D) Percent target cell cytotoxicity. (B) NK-92 or (D) mouse OT1 T cells were incubated with   
 K562 cells for 4 hrs or B16F10-OVA targets or 24 hrs, respectively, at a 10:1 E: T ratio (n = 3). 
 
 
 
A B 
C D 
  
  
    
  
 
122 
 
7.5 NK Cytolysis Activity Toward BPTF KD Cells is Conserved in Human 
   In a first step toward understanding the mechanism for the enhanced cytolytic 
activity of NK cells to BPTF KD tumor cells, we determined if the effect is conserved 
between mice and humans. Toward this end, we transduced the human breast 
adenocarcinoma cell lines, T47D and MDA-MB-436, and the neuroblastoma cell line 
SH-SY5Y with lentiviruses expressing control or BPTF shRNAs (Figure 7.9 A, B). These 
human cell lines and the mouse 67NR and 66cl4 cell lines were cocultured with human 
NK-92 cells, an immortalized human NK cell line (Gong et al., 1994), and monitored for 
cytolytic activity. Similarly, we observed enhanced NK-92 cytolytic activity toward 
human BPTF KD targets compared to controls (Figure 7.9 C). Moreover, the levels of 
heparanase were also down regulated in these cells indicating that the mechanisms 
leading to NK enhanced cytolytic activity are conserved. 
 Collectively, our data suggest a model for BPTF in the suppression of NK 
antitumor activity as shown in Figure 7.10. BPTF is a positive regulator of heparanase in 
67NR and 66cl4 cells and its depletion increases cell surface HSPG levels. HSPGs are 
activating ligands for the NK cells activating receptor NCR1 (in mouse) and NKp30 (in 
human), and their abundance on the cell surface made them better targets for NK cells 
cytolytic activity. In addition, active NK cells secrete IFNγ, which promotes the Th1 
response, which in turn secrete more IFNγ that activate APCs and recruit more immune 
effector cells. We speculate that dead tumor cells in the TME result in more de novo 
antigens and enhance CD8 T cells effector function upon presentation. The combined 
effect of these responses promotes tumor elimination and host protection. 
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Figure 7.9: NK Cytolysis Activity is Conserved in Human Cell Lines. 
A) BPTF Western blot analysis of heparanase in control and BPTF KD T47D, MDA-MB-436 and SH-
SY5Y total cell extracts. This is done by Dr.Joseph Landry.  
B) qRT-PCR analysis of heparanase expression in T47D, MDA-MB-436 and SH-SY5Y cells (n = 3, * = t-
test p-value < 0.05). This is done by Kimberly Mayes. 
C) NK-92 cells were co-cultured with T47D, MDA-MD-436 or SH-SY5Y at a 10:1 E: T ratio (n = 3, * = t-
test p-value < 0.05). 
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Figure 7.10: A Model for BPTF Suppression of Anti-Tumor Activity. 
In BPTF Ctrl cells, NURF stimulates heparanase expression, which consequently reduces cell surface 
HSPGs (NCR1 co-ligand) abundance, inhibiting NK-cell antitumor activity. However, in BPTF KD cells, 
heparanase levels are reduced resulting in elevated HSPGs on the cell surface and enhancement of NK 
cell-mediated antitumor activity.   
 
 
 
 
 
 
 
 
 
 
A Model for the Effect of BPTF KD in Anti-Tumor Immunity  
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Chapter 8 
Discussion and Future Directions 
 
Tumor immune evasion is an important step for cancer progression, which is 
accomplished by acquiring genetic and epigenetic modifications. These changes can 
result in defective antigen presentation, upregulation of immune suppressive mediators 
and/or down regulation of NK ligands for activating receptors (Vinay et al., 2015).  
Genetic changes are irreversible and occur at lower frequency than reversible 
epigenetic changes making them appealing therapeutic targets (Kornel et al., 2007). 
ATP dependent chromatin remodeling complexes are gate-keepers that regulate the 
accessibility to DNA or histone modifiers predicting an essential role for these 
complexes in cancer biology. To understand how the ATP dependent remodeling 
complex NURF is involved in breast cancer progression, we used mouse transplantable 
tumor models. In these models BPTF KD induced NK antitumor response and polarized 
TME toward tumor rejection and eradication by inducing Th1 response. 
BPTF is the largest and essential subunit of the NURF complex (Barak et al., 
2003, Xiao et al., 2001). BPTF is unique subunit for the NURF complex so; its 
knockdown will not cause pleotropic effects that could complicate our results. BPTF has 
a tumorigenic role in skin, lung, colon and liver (Dai et al., 2015, Xiao et al., 2015, 
Buganim et al., 2010, Xiao et al., 2015). However, its exact role in breast cancer biology 
is not well understood. To uncover its roles in breast cancer biology we used well-
characterized mouse models of breast cancer. The cell lines used in this study (67NR,  
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66cl4 and 4T1) were isolated from same tumor (Aslakson and Miller, 1992). Both 4T1 
and 66cl4 cell lines are metastatic while 67NR is not. 4T1 is highly immunogenic and it 
is characterized by high infiltration rate of suppressive immune cells such as immature 
DCs, Tregs, MDSCs and both M1&M2 macrophages (Aslakson and Miller, 1992 and 
Zaidi et al., 2011). However, the immunogenicity of both 67NR and 66cl4 is not defined. 
BPTF knock-down in both immunogenic and non-immunogenic cell lines resulted in 
reduced tumor weights suggesting that BPTF depletion can overcome immune 
suppressive mechanisms developed by tumor cells. Our depletion experiments revealed 
that NK are the major effector cells involved in the reduction of BPTF KD cells. NK cells 
represent the key component of the innate immune system that recognize and eliminate 
cancer cells. There is recent clinical and experimental evidence that NK cells are 
critically involved in the immune surveillance of tumors (Waldhauer and Steinle 2008). 
     NK cell cytotoxic activity results from the integration of multiple activating and 
inhibitory signals (Chester et al., 2015). We looked at the levels of NK inhibitory ligands 
but they were expressed equally on both Ctrl and BPTF KD targets (data not shown). 
We also tested the possibility that BPTF KD targets secrete a soluble factor to activate 
NK cells. These experiments  revealed that NK activity is due to a cell surface receptor 
rather than a soluble ligand (data not shown). To complete cytotoxicity assays we took 
advantage of NK-92, a highly cytotoxic human cell line that is IL-2-dependent (Guitta et 
al., 2000). NK-92 express high levels of activating receptors such as NKp30, NKp46, 
and 2B4, NKG2D, E and CD28 and the expression levels of cytotoxic molecules such 
as perforins and-granzymes are also high (Guitta et al., 2000).  Conversely, they  
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express few inhibitory receptors like NKG2A/B very low levels of KIR2DL4 and ILT-2 
lack most the killer inhibitory receptors (KIRs). The increased cytotoxic activity of NK-92 
cells toward BPTF KD targets supports the presence of a conserved active receptor-
ligand between mice and human that is responsible for their enhanced activity. These 
results also excluded the possibility of an antibody dependent cell cytotoxicity (ADCC) 
since NK-92 do not express the FC-gamma receptor. 
Our microarray data support the role of BPTF in regulating HSPGs (data not 
shown) leading us to a defined set of activating receptors on NK-92 cells (NCRs- 
NKp30, NKp44 and NKp46) and their conserved homologue in mice NCR1. Antibody 
blocking and heparin competitive inhibition experiments revealed that NKp30 (and 
NCR1 in mice) is most likely to be the target receptor. The NKp30 is involved in the 
crosstalk between NK cells and immature dendritic cells (iDCs) (Simhadri, and Reiners 
et al. 2008).  The cross-talk may either result in a reciprocal activation and maturation of 
both cell types or in NK cell-dependent killing of immature dendritic cells, a mechanism 
that limits the supply of antigen-presenting DCs to the immune response (Walzer, Dalod 
et al. 2005). In this crosstalk, NKp30 on NK cells seems to be the driving and critical 
receptor for both processes (Ferlazzo, Tsang et al. 2002; Vitale, Della Chiesa et al. 
2005; Walzer, Dalod et al. 2005; Simhadri, Reiners et al. 2008).   
We used two approaches to support our finding; the first approach was the use of 
NCR-Fc soluble receptors that bind their cognate ligands if expressed on target cells. 
Although the binding of both BPTF Ctrl and KD targets was similar, the second  
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approach was enhancement of IL-2 expression in BW reporter cell line. Although both 
Ctrl and BPTF KD targets bind equally to NCR1-Fc BPTF KD targets enhanced more 
IL-2 expression when in contact with the Ncr1-zeta BW reporter line. This could be 
explained by different glycosylation pattern of the Ncr1 receptor in BW and HEK-293 
cells which results in differential ligand binding (Ariella et al., 2015). Another possibility 
is that BPTF KD targets expresses adhesion molecules that synergize with NCR1 and 
enhance IL-2 expression. 
We have attributed the lower levels of HSPGs on BPTF Ctrl cells to higher 
expression levels of heparanase. Higher levels of heparanase expression was 
supported experimentally by Western blot and QPCR analysis. The BPTF dependent 
regulation of heparanase could be direct due to the fact that BPTF occupies the 
heparanase promoter region as illustrated by CHIP analysis. BPTF regulation of 
heparanase expression could have broader implications since heparanase is involved in 
many tumor promoting processes such as angiogenesis, metastasis, and inflammation 
(Hammond et al., 2014). It has been shown that BPTF KD in melanoma tumors reduced 
their metastatic potential (Dar et al., 2015). Our data suggest that BPTF could reduce 
metastasis through heparanase regulation. The connection between BPTF depletion 
and heparanase down-regulation and their effect on metastasis needs to be further 
tested.  
  In our model, depletion of BPTF in established tumors overcame the 
suppressive effect of TME and enhanced NK cytotoxic function. Antitumor activity of NK 
cells could be direct or indirect. The direct effect of NK cells is lysis of tumor cells and  
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secretion of IFNγ. IFNγ secretion in the TME can indirectly enhance Th1 cells to control 
tumor growth (Ribas et al., 2003). In addition, because of IFNγ secretion, tumor cells 
induce Fas expression and NK cells can kill them in a Fas ligand-dependent manner, 
the lysis of tumor cells release de novo antigens, which in turn enhance tumor 
antigenicity (Screpanti et al., 2001). Moreover, IFNγ stimulate the maturation of dendritic 
cells, which promote strong and protective CD8 T cell response (Mocikat et al., 2003; 
Adam et al., 2005). For 4T1 tumors, IFNγ is secreted by T cells, which can activate 
antitumor T cells and promote the production of nitric oxide synthetase (Shankaran et 
al., 2001). High levels of NO (nitric oxide) in the TME can directly induce apoptosis 
through caspase activation, DNA fragmentation and chromatin condensation (Dimmeler 
et al., 1997, Brune et al., 1998). Finally, BPTF depletion in 66cl4 or 4T1 tumors enhance 
immune effector cells activity generating a positive feedback loop that helps in tumor 
elimination (Heba et al., 2011). 
 BPTF depletion in 66cl4 tumors with rADV resulted in complete tumor regression 
in about 18% of the mice. This regression was not observed in 4T1 tumors possibly due 
to (i) 66cl4 tumors are infiltrated by significantly large number of NK cells, which upon 
activation by BPTF depletion can completely eradicate tumors (Figure 7.2 A). In 
addition, 4T1 cells is infiltrated by significant number of MDSCs, which are suppressive 
immune cells. Although we treated the mice with gemcitabine (Le et al., 2009) to 
eliminate MDSCs, the inability to achieve tumor regression could be a result of their 
residual activity. In the future, we can try high concentration of the rADV to treat 4T1 
tumors to get a similar response to 66cl4. 
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BPTF depletion could synergize with other epigenetic modification inhibitors such 
as the currently used DNMTi (DNA methyltransferase inhibitors). DNMTi are 
demethylation agents that are known to induce the immune response by removing the 
methylation suppressive effect on tumor antigens such as cancer testis antigens (CTAs) 
and stimulating a CD8+ T cell response (James et al., 2006). DNMTis are also known to 
induce heparanase expression possibly by promoting cancer biology (Ateeq et al., 
2008; Shteper et al., 2003). Combination of DNMTi and NURF inhibitors could possibly 
inhibit heparanase upregulation, enhance CD8 T, cells and synergize with the beneficial 
antitumor immune response by enhancing NK cells antitumor activities. 
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